PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17885626-0 2007 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Tacrolimus 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Tacrolimus 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 174-188 17391324-0 2007 Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Tacrolimus 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 17568575-0 2007 Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Tacrolimus 160-170 ATP binding cassette subfamily B member 1 Homo sapiens 86-91 17635182-0 2007 Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 63-105 17635182-0 2007 Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 17635182-2 2007 P-glycoprotein (P-gp), encoded by the adenosine triphosphate-binding cassette B1 (ABCB1) and the cytochrome (CYP) 3A4 and 3A5 enzymes appears to play a role in the tacrolimus metabolism. Tacrolimus 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 17635182-2 2007 P-glycoprotein (P-gp), encoded by the adenosine triphosphate-binding cassette B1 (ABCB1) and the cytochrome (CYP) 3A4 and 3A5 enzymes appears to play a role in the tacrolimus metabolism. Tacrolimus 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 17635182-2 2007 P-glycoprotein (P-gp), encoded by the adenosine triphosphate-binding cassette B1 (ABCB1) and the cytochrome (CYP) 3A4 and 3A5 enzymes appears to play a role in the tacrolimus metabolism. Tacrolimus 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 38-80 17635182-2 2007 P-glycoprotein (P-gp), encoded by the adenosine triphosphate-binding cassette B1 (ABCB1) and the cytochrome (CYP) 3A4 and 3A5 enzymes appears to play a role in the tacrolimus metabolism. Tacrolimus 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 82-87 17889118-3 2007 The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes. Tacrolimus 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 228-242 17889118-3 2007 The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes. Tacrolimus 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 263-285 17889118-3 2007 The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes. Tacrolimus 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 287-291 17889118-4 2007 A number of retrospective studies that demonstrated a link between the polymorphisms governing the CYP3A5 protein expression, with more conflicting results with the MDR1 gene polymorphisms, related to the daily dose necessary to achieve adequate blood tacrolimus levels. Tacrolimus 252-262 ATP binding cassette subfamily B member 1 Homo sapiens 165-169 17031644-9 2007 CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations. Tacrolimus 18-28 ATP binding cassette subfamily B member 1 Homo sapiens 70-73 17031644-9 2007 CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations. Tacrolimus 18-28 ATP binding cassette subfamily B member 1 Homo sapiens 75-80 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Tacrolimus 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 190-193 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Tacrolimus 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 195-200 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Tacrolimus 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 203-233 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Tacrolimus 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 235-240 17603267-6 2007 In this paper, we review the population pharmacokinetic and pharmacogenomic analysis of tacrolimus, focusing on an efflux transporter P-glycoprotein (multidrug resistance 1 [MDR1/ABCB1]) and drug-metabolizing enzymes cytochrome P450 (CYP) 3A4 and 3A5, and describe Bayesian forecasting to individualize the tacrolimus dose in de novo living-donor liver transplant recipients. Tacrolimus 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 134-172 17603267-6 2007 In this paper, we review the population pharmacokinetic and pharmacogenomic analysis of tacrolimus, focusing on an efflux transporter P-glycoprotein (multidrug resistance 1 [MDR1/ABCB1]) and drug-metabolizing enzymes cytochrome P450 (CYP) 3A4 and 3A5, and describe Bayesian forecasting to individualize the tacrolimus dose in de novo living-donor liver transplant recipients. Tacrolimus 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 174-178 17603267-6 2007 In this paper, we review the population pharmacokinetic and pharmacogenomic analysis of tacrolimus, focusing on an efflux transporter P-glycoprotein (multidrug resistance 1 [MDR1/ABCB1]) and drug-metabolizing enzymes cytochrome P450 (CYP) 3A4 and 3A5, and describe Bayesian forecasting to individualize the tacrolimus dose in de novo living-donor liver transplant recipients. Tacrolimus 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 179-184 17603267-6 2007 In this paper, we review the population pharmacokinetic and pharmacogenomic analysis of tacrolimus, focusing on an efflux transporter P-glycoprotein (multidrug resistance 1 [MDR1/ABCB1]) and drug-metabolizing enzymes cytochrome P450 (CYP) 3A4 and 3A5, and describe Bayesian forecasting to individualize the tacrolimus dose in de novo living-donor liver transplant recipients. Tacrolimus 307-317 ATP binding cassette subfamily B member 1 Homo sapiens 174-178 17603267-6 2007 In this paper, we review the population pharmacokinetic and pharmacogenomic analysis of tacrolimus, focusing on an efflux transporter P-glycoprotein (multidrug resistance 1 [MDR1/ABCB1]) and drug-metabolizing enzymes cytochrome P450 (CYP) 3A4 and 3A5, and describe Bayesian forecasting to individualize the tacrolimus dose in de novo living-donor liver transplant recipients. Tacrolimus 307-317 ATP binding cassette subfamily B member 1 Homo sapiens 179-184 17377957-0 2007 Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Tacrolimus 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 17377957-1 2007 The objective of this study was to evaluate whether genetic polymorphisms of CYP2C19, CYP3A5 and MDR1 significantly impact the interaction between tacrolimus and rabeprazole or lansoprazole. Tacrolimus 147-157 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 17015051-10 2006 CONCLUSIONS: The enterocyte MDR1 mRNA level and the CYP3A5*1 allele in the graft liver contribute differently to the interindividual variability in the oral clearance of tacrolimus after living-donor liver transplantation. Tacrolimus 170-180 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 17268068-0 2007 P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. Tacrolimus 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 17268068-2 2007 A drug efflux pump P-glycoprotein (P-gp) actively transports FK506 out of target cells, thereby reducing their efficacy. Tacrolimus 61-66 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 17268068-2 2007 A drug efflux pump P-glycoprotein (P-gp) actively transports FK506 out of target cells, thereby reducing their efficacy. Tacrolimus 61-66 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 17268068-3 2007 We investigated the influence of FK506 therapy on the P-gp function of peripheral-blood mononuclear cells (PBMCs) in MG patients. Tacrolimus 33-38 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 17268068-9 2007 The data raise the possibility that FK506 treatment attenuated P-gp function in the PBMCs of the MG patients. Tacrolimus 36-41 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 17106006-8 2006 The influences of CYP3A5 alleles on cyclosporine metabolism and the MDR1 C3435T polymorphism on tacrolimus metabolism remain controversial. Tacrolimus 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 17112846-0 2006 Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 17112846-2 2006 P-glycoprotein (P-gp) plays an important role in the absorption metabolism of tacrolimus. Tacrolimus 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 17112846-2 2006 P-glycoprotein (P-gp) plays an important role in the absorption metabolism of tacrolimus. Tacrolimus 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 17112846-6 2006 The results showed a significant association between tacrolimus levels per dose mg/kg/d and MDR1 gene C3435T polymorphism (P < .05). Tacrolimus 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 17190370-1 2006 OBJECTIVE: Lansoprazole and tacrolimus are substrates of ATP binding cassette (ABC) transporters such as P-glycoprotein (ABCBI/multidrug resistance 1) and cytochrome P450 (CYP). Tacrolimus 28-38 ATP binding cassette subfamily B member 1 Homo sapiens 121-149 17190370-2 2006 The purpose of this study was to investigate the implication of the ABCB1 C3435Tpolymorphism on the pharmacokinetics of (R)-lansoprazole, the major enantiomer, in CYP2C19 extensive metabolizers (EMs) and on gastroesophageal symptoms in renal transplant recipients receiving tacrolimus. Tacrolimus 274-284 ATP binding cassette subfamily B member 1 Homo sapiens 68-73 17049058-1 2006 Genetic polymorphisms in biotransformation enzyme CYP3A5 (6986G > A, CYP3A5*3; 14690A > G, CYP3A5*6) and drug transporter ABCB1 (1236C > T; 2677G > T/A; 3435C > T) are known to influence tacrolimus (Tac) dose requirements and trough blood levels in stable transplant patients. Tacrolimus 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 128-133 16906020-0 2006 Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Tacrolimus 48-58 ATP binding cassette subfamily B member 1 Homo sapiens 20-25 16969296-0 2006 Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Tacrolimus 73-83 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 16969296-2 2006 Variability in tacrolimus absorption is influenced by P-gp activity which, in turn, is affected by single nucleotide polymorphisms (SNPs) within the multidrug resistance-1 gene (MDR-1). Tacrolimus 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 16969296-2 2006 Variability in tacrolimus absorption is influenced by P-gp activity which, in turn, is affected by single nucleotide polymorphisms (SNPs) within the multidrug resistance-1 gene (MDR-1). Tacrolimus 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 149-171 16969296-2 2006 Variability in tacrolimus absorption is influenced by P-gp activity which, in turn, is affected by single nucleotide polymorphisms (SNPs) within the multidrug resistance-1 gene (MDR-1). Tacrolimus 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 178-183 16969296-3 2006 Tacrolimus dose requirements of 206 stable renal transplant patients were related to MDR-1 genotypes of SNPs C1236T, G2677T/A and C3435T, as well as haplotypes: C-G-C and T-T-T. Lower dose-normalized blood tacrolimus concentrations were achieved for: 2677-GG genotype patients, as compared to 2677-TT, and for 3435-CC patients as compared to 3435-TT patients. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 85-90 16969296-6 2006 Our data suggest that MDR-1 haplotypes have a relatively minor association with tacrolimus pharmacokinetics. Tacrolimus 80-90 ATP binding cassette subfamily B member 1 Homo sapiens 22-27 16759707-5 2006 Both tacrolimus and cyclosporine are substrates of Pgp, CYP3A4 and CYP3A5, and therefore, these molecules are potential pharmacokinetic factors with which to establish personalized dosage regimens for these drugs. Tacrolimus 5-15 ATP binding cassette subfamily B member 1 Homo sapiens 51-54 16759707-7 2006 In living-donor liver transplant (LDLT) patients, the intestinal mRNA expression level of MDR1 and CYP3A5 genotyping both in the native intestine and in the grafted liver are suggested to be potential pharmacokinetic factors for adjusting initial dosage and predicting post-operative variation in the pharmacokinetics of tacrolimus. Tacrolimus 321-331 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 16906020-2 2006 Cytochrome P450 3A4 (Cyp3A4) and Cyp3A5 are the most important contributors to tacrolimus metabolism while the P-glycoprotein pump (MDR-1) modulates its bioavailability. Tacrolimus 79-89 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 16906020-3 2006 The objective was to investigate the association between Cyp3A4, Cyp3A5, and MDR-1 polymorphisms and tacrolimus pharmacokinetics in the early period after renal transplantation. Tacrolimus 101-111 ATP binding cassette subfamily B member 1 Homo sapiens 77-82 16906020-8 2006 Patients with less than three copies of MDR-1 (T-129C, C3435T and G2677T) polymorphisms, associated with reduced expression of P-glycoprotein, had also lower dose-adjusted tacrolimus blood concentrations compared to patients having equal to or greater than three copies of MDR-1 genetic variants (P=0.003). Tacrolimus 172-182 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 16906020-8 2006 Patients with less than three copies of MDR-1 (T-129C, C3435T and G2677T) polymorphisms, associated with reduced expression of P-glycoprotein, had also lower dose-adjusted tacrolimus blood concentrations compared to patients having equal to or greater than three copies of MDR-1 genetic variants (P=0.003). Tacrolimus 172-182 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 16906020-8 2006 Patients with less than three copies of MDR-1 (T-129C, C3435T and G2677T) polymorphisms, associated with reduced expression of P-glycoprotein, had also lower dose-adjusted tacrolimus blood concentrations compared to patients having equal to or greater than three copies of MDR-1 genetic variants (P=0.003). Tacrolimus 172-182 ATP binding cassette subfamily B member 1 Homo sapiens 273-278 16906020-10 2006 CONCLUSION: The complete absence of Cyp3A5*3 allele and the accumulation of less than three copies of MDR-1 (T-129C, C3435T and G2677T) polymorphisms are associated with lower tacrolimus blood levels identifying these genotypes as markers for patients requiring higher tacrolimus doses. Tacrolimus 176-186 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 16906020-10 2006 CONCLUSION: The complete absence of Cyp3A5*3 allele and the accumulation of less than three copies of MDR-1 (T-129C, C3435T and G2677T) polymorphisms are associated with lower tacrolimus blood levels identifying these genotypes as markers for patients requiring higher tacrolimus doses. Tacrolimus 269-279 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 16753004-0 2006 Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Tacrolimus 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 16911928-6 2006 RESULTS: The SNPs of CYP3A and P-gp are closely correlated to the large variations of cyclosporine and tacrolimus dosage between different patients, although conflicting results were obtained by some authors. Tacrolimus 103-113 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 16753004-2 2006 The cytochrome P450 3A (CYP3A) and the ATP-binding cassette B1 (ABCB1) genes play an important role in the tacrolimus disposition. Tacrolimus 107-117 ATP binding cassette subfamily B member 1 Homo sapiens 39-62 16753004-2 2006 The cytochrome P450 3A (CYP3A) and the ATP-binding cassette B1 (ABCB1) genes play an important role in the tacrolimus disposition. Tacrolimus 107-117 ATP binding cassette subfamily B member 1 Homo sapiens 64-69 16797284-0 2006 The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Tacrolimus 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 16797284-0 2006 The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Tacrolimus 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 20-25 16628701-0 2006 Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 63-68 16628701-1 2006 The aim of this study was to investigate whether the heterogeneity in tacrolimus dose requirement is associated with ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients during the first month after transplantation. Tacrolimus 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 16628701-7 2006 The tacrolimus C/D ratios were obviously lower in recipients carrying ABCB1 3435CC genotype. Tacrolimus 4-14 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 16628701-10 2006 Analysis of the combination of recipients" ABCB1 and donors" CYP3A5 genotypes revealed that the tacrolimus C/D ratios were significantly lower in the ABCB1 3435CC-carrying recipients, regardless of donors" CYP3A5 genotype. Tacrolimus 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 150-155 16628701-11 2006 In conclusion, our finding suggests that the recipients" ABCB1 and donors" CYP3A5 genotype affect the tacrolimus dose requirements. Tacrolimus 102-112 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 16628701-12 2006 ABCB1 C3435T polymorphism is a major determinant of tacrolimus trough concentration in Chinese liver transplant recipients, and recipients with 3435CC genotype will require higher dose of tacrolimus. Tacrolimus 52-62 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 16628701-12 2006 ABCB1 C3435T polymorphism is a major determinant of tacrolimus trough concentration in Chinese liver transplant recipients, and recipients with 3435CC genotype will require higher dose of tacrolimus. Tacrolimus 188-198 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 17032130-0 2006 The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Tacrolimus 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 66-71 16424824-1 2006 It has been reported that hepatic and intestinal cytochrome P450 (CYP) 3A4, CYP3A5 and P-glycoprotein affect the pharmacokinetics of tacrolimus, and that these proteins are associated with the large inter-individual variation in the pharmacokinetics of this drug. Tacrolimus 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 16418689-4 2006 The most extensive blood concentration/dose information available is on tacrolimus and its dosing related to CYP3A5 and ABCB1 gene polymorphisms. Tacrolimus 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 120-125 17032130-1 2006 BACKGROUND: Cytochrome P450 3A5 (CYP3A5) and ABCB1 polymorphisms have been shown to influence tacrolimus (Tc) blood concentrations in the stable phase after organ transplantation. Tacrolimus 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 17032130-1 2006 BACKGROUND: Cytochrome P450 3A5 (CYP3A5) and ABCB1 polymorphisms have been shown to influence tacrolimus (Tc) blood concentrations in the stable phase after organ transplantation. Tacrolimus 106-108 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 16431292-0 2006 Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Tacrolimus 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 16413244-6 2006 The mRNA expression level of MDR1 was inversely correlated with the tacrolimus concentration-oral dose ratio during the initial 4 days after surgery in patients with a graft-to-recipient weight ratio greater than 1.5 (r= -0.6798, P< .0001) and those with a graft-to-recipient weight ratio of less than 1.5 (r= -0.7180, P< .0001). Tacrolimus 68-78 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 16431292-0 2006 Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Tacrolimus 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 16431292-1 2006 BACKGROUND: The influence of ABCB1 (MDR1) polymorphisms on tacrolimus dosing has been questioned in previous studies with contradictory findings, possibly due to the association between CYP3A5 polymorphisms and tacrolimus dosing. Tacrolimus 59-69 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 16431292-1 2006 BACKGROUND: The influence of ABCB1 (MDR1) polymorphisms on tacrolimus dosing has been questioned in previous studies with contradictory findings, possibly due to the association between CYP3A5 polymorphisms and tacrolimus dosing. Tacrolimus 59-69 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 16431292-1 2006 BACKGROUND: The influence of ABCB1 (MDR1) polymorphisms on tacrolimus dosing has been questioned in previous studies with contradictory findings, possibly due to the association between CYP3A5 polymorphisms and tacrolimus dosing. Tacrolimus 211-221 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 16431292-1 2006 BACKGROUND: The influence of ABCB1 (MDR1) polymorphisms on tacrolimus dosing has been questioned in previous studies with contradictory findings, possibly due to the association between CYP3A5 polymorphisms and tacrolimus dosing. Tacrolimus 211-221 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 16431292-2 2006 The objective of this study was to assess the effect of ABCB1 haplotypes from 3 distinct polymorphic sites on the tacrolimus level/dose [L/D] in lung transplant patients limited to CYP3A5 *3/*3 non-expressors. Tacrolimus 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 16431292-10 2006 CONCLUSION: This study demonstrates that ABCB1 haplotypes derived from three common polymorphisms are associated with tacrolimus dosing in lung transplant patients when eliminating the confounder CYP3A5 genotype. Tacrolimus 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 41-46 16409819-0 2005 [Relationship between MDR1 gene polymorphism and blood concentration of tacrolimus in renal transplant patients]. Tacrolimus 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 16409819-1 2005 OBJECTIVE: To investigate the relationship between MDR1 exon 21 and exon 26 polymorphism and whole blood concentration of tacrolimus (FK506) in renal transplant patients. Tacrolimus 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 16409819-1 2005 OBJECTIVE: To investigate the relationship between MDR1 exon 21 and exon 26 polymorphism and whole blood concentration of tacrolimus (FK506) in renal transplant patients. Tacrolimus 134-139 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 16409819-9 2005 Three, six, and twelve months after the transplantation a significant correlation between the whole blood FK506 concentration per dose/day and MDR1 exon 21 and exon 26 genotypes. Tacrolimus 106-111 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 16409819-14 2005 CONCLUSIONS: The MDR1 gene polymorphism is correlated with the whole blood concentration of FK506. Tacrolimus 92-97 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 15919446-3 2005 For 7 days postoperatively, good inverse correlation was found between the tacrolimus concentration/dose (C/D) ratio and the intestinal mRNA level of MDR1 (r = -0.776), but not of CYP3A4 (r = -0.096), in the 46 cases. Tacrolimus 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 150-154 16249748-0 2005 Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Tacrolimus 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 16249748-1 2005 BACKGROUND: CYP3A5 and MDR1 polymorphisms have been shown to influence tacrolimus blood concentrations and dose requirements. Tacrolimus 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 16249748-7 2005 CYP3A5 (intron 3) and MDR1 (exons 12, 21, 26) genotypes were correlated to the adjusted trough concentrations and dose requirements for both sirolimus and tacrolimus. Tacrolimus 155-165 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 16146556-2 2005 Cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp, encoded by MDR1) play an important role in the absorption and metabolism of tacrolimus. Tacrolimus 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 16146556-2 2005 Cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp, encoded by MDR1) play an important role in the absorption and metabolism of tacrolimus. Tacrolimus 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 16416180-0 2005 A higher dose requirement of tacrolimus in active Crohn"s disease may be related to a high intestinal P-glycoprotein content. Tacrolimus 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 102-116 16416180-1 2005 Tacrolimus, a relatively new therapeutic option for patients with corticosteroid-refractory Crohn"s disease or ulcerative colitis, is a substrate for the apically directed efflux transporter P-glycoprotein (P-gp). Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 191-205 16416180-1 2005 Tacrolimus, a relatively new therapeutic option for patients with corticosteroid-refractory Crohn"s disease or ulcerative colitis, is a substrate for the apically directed efflux transporter P-glycoprotein (P-gp). Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 207-211 16416180-4 2005 Elevated intestinal P-gp could have resulted in decreased tacrolimus absorption, thereby leading to decreased blood concentration and decreased efficacy in this patient. Tacrolimus 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 20-24 16331555-0 2005 Impact of multidrug resistance 1 gene polymorphism on tacrolimus dose and concentration-to-dose ratio in Chinese liver transplantation recipients. Tacrolimus 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 10-32 16331555-1 2005 OBJECTIVE: To investigate whether the polymorphism of multidrug resistance 1 gene (MDR1) in the donors and liver transplantation recipients was correlated with interindividual variation in tacrolimus dose requirement and concentration-to-dose ratio. Tacrolimus 189-199 ATP binding cassette subfamily B member 1 Homo sapiens 54-76 16331555-1 2005 OBJECTIVE: To investigate whether the polymorphism of multidrug resistance 1 gene (MDR1) in the donors and liver transplantation recipients was correlated with interindividual variation in tacrolimus dose requirement and concentration-to-dose ratio. Tacrolimus 189-199 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 16331555-5 2005 Tacrolimus doses required to achieve target blood concentrations were higher in the patients with MDR1 CC genotype than in the CT or TT genotype patients, and the dose-adjusted trough levels were lower. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 16331555-7 2005 CONCLUSION: Tacrolimus dose requirement and dose-adjusted trough levels were correlated with MDR1 3435 (C-->T) polymorphism, and MDR1 3435 (C-->T) polymorphism analysis is helpful to individualize tacrolimus administration. Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 16331555-7 2005 CONCLUSION: Tacrolimus dose requirement and dose-adjusted trough levels were correlated with MDR1 3435 (C-->T) polymorphism, and MDR1 3435 (C-->T) polymorphism analysis is helpful to individualize tacrolimus administration. Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 16146556-0 2005 Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Tacrolimus 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 16146556-2 2005 Cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp, encoded by MDR1) play an important role in the absorption and metabolism of tacrolimus. Tacrolimus 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 29-43 15919446-0 2005 Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. Tacrolimus 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 15919446-4 2005 After classifying the patients according to median of the intestinal MDR1 mRNA expression, the oral dose of tacrolimus in the high-MDR1 group was approximately twofold higher than in the low-MDR1 group (P < .001), whereas its trough level was similar between the two groups. Tacrolimus 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 15919446-4 2005 After classifying the patients according to median of the intestinal MDR1 mRNA expression, the oral dose of tacrolimus in the high-MDR1 group was approximately twofold higher than in the low-MDR1 group (P < .001), whereas its trough level was similar between the two groups. Tacrolimus 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 15919446-4 2005 After classifying the patients according to median of the intestinal MDR1 mRNA expression, the oral dose of tacrolimus in the high-MDR1 group was approximately twofold higher than in the low-MDR1 group (P < .001), whereas its trough level was similar between the two groups. Tacrolimus 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 15919446-5 2005 In addition, the correlation between the intestinal MDR1 mRNA level and the tacrolimus C/D ratio was confirmed with a larger population (r = -0.645, n = 104). Tacrolimus 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 15919446-6 2005 Using the regression line between the intestinal MDR1 mRNA level and tacrolimus C/D ratio, we could prospectively predict the individual C/D ratio of tacrolimus immediately after LDLT. Tacrolimus 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 15919446-6 2005 Using the regression line between the intestinal MDR1 mRNA level and tacrolimus C/D ratio, we could prospectively predict the individual C/D ratio of tacrolimus immediately after LDLT. Tacrolimus 150-160 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 15919446-8 2005 This suggests that the intestinal mRNA level of MDR1 is a useful molecular marker for determination of the personalized oral dose of tacrolimus in recipients of LDLT immediately after surgery. Tacrolimus 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 15919447-0 2005 Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Tacrolimus 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 15919447-0 2005 Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Tacrolimus 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 15919447-1 2005 OBJECTIVE: The objective of this study was to assess the influence of CYP3A5 and MDR1 genetic polymorphisms on tacrolimus pharmacokinetics in Japanese renal transplant recipients. Tacrolimus 111-121 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 15919447-7 2005 In this study, a distinction was made between carriers of CYP3A5*1/*1+*1/*3 and CYP3A5*3/*3 to investigate the influence of the MDR1 C3435T mutation on tacrolimus pharmacokinetics. Tacrolimus 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 15778421-0 2005 Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. Tacrolimus 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 80-85 15778421-1 2005 The genetic polymorphisms in the ABCB1 gene, which encodes for the membrane pump, P-glycoprotein, have been previously demonstrated to have an association with tacrolimus dosing in organ transplant patients. Tacrolimus 160-170 ATP binding cassette subfamily B member 1 Homo sapiens 33-38 15778421-1 2005 The genetic polymorphisms in the ABCB1 gene, which encodes for the membrane pump, P-glycoprotein, have been previously demonstrated to have an association with tacrolimus dosing in organ transplant patients. Tacrolimus 160-170 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 15778421-4 2005 Sequential analysis demonstrated that ABCB1 genotypes 00 and 01 had low tacrolimus [L/D] values at 1 and 3 months, but these values increased substantially at 6, 9, and 12 months after transplantation. Tacrolimus 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 38-43 15778421-6 2005 Haplotype analysis also suggested that the homozygous for ABCB1 2677 variant allele had more of an impact on tacrolimus [L/D] in haplotype analysis than that of ABCB1 3435. Tacrolimus 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 58-63 15502717-0 2004 Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Tacrolimus 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 16038570-5 2005 It is also a substrate for P-glycoprotein, which counter-transports diffused tacrolimus out of intestinal cells and back into the gut lumen. Tacrolimus 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 16038570-6 2005 Age-associated alterations in CYP 3A and P-glycoprotein expression and/or activity, along with liver mass and body composition changes, would be expected to affect the pharmacokinetics of tacrolimus in the elderly. Tacrolimus 188-198 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 15383495-2 2004 Tacrolimus absorption from the gastrointestinal tract is to a large extent determined by the genotypic, phenotypic, and functional expression of P-glycoprotein and CYP3A in the gut wall and liver. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 145-159 15698457-0 2005 Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Tacrolimus 96-101 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 15698457-1 2005 BACKGROUND: Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) are important determinants of the oral bioavailability and clearance of tacrolimus. Tacrolimus 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 45-59 15698457-1 2005 BACKGROUND: Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) are important determinants of the oral bioavailability and clearance of tacrolimus. Tacrolimus 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 61-64 15882134-5 2005 This review describes polymorphisms of the genes coding for P-gp and CYPs, and focuses on the compounds cyclosporin and tacrolimus. Tacrolimus 120-130 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 15521904-1 2004 AIM: This retrospective study investigated the influence of MDR1 haplotypes derived from the polymorphisms 2677G > T (exon 21) and 3435C > T (exon 26) on the pharmacokinetics of the immunosuppressant drug tacrolimus in 73 renal transplant patients. Tacrolimus 211-221 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 15502717-0 2004 Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Tacrolimus 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 15502717-2 2004 Tacrolimus is a substrate for cytochrome P450 (CYP) 3A5 and p-glycoprotein encoded by CYP3A5 and MDR1 (ABCB1), respectively, having multiple single nucleotide polymorphisms. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 60-74 15502717-2 2004 Tacrolimus is a substrate for cytochrome P450 (CYP) 3A5 and p-glycoprotein encoded by CYP3A5 and MDR1 (ABCB1), respectively, having multiple single nucleotide polymorphisms. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 15502717-2 2004 Tacrolimus is a substrate for cytochrome P450 (CYP) 3A5 and p-glycoprotein encoded by CYP3A5 and MDR1 (ABCB1), respectively, having multiple single nucleotide polymorphisms. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 15060513-0 2004 Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 15226679-7 2004 An analysis of the combination of intestinal MDR1 level and liver CYP3A5 genotype revealed that the tacrolimus C/D ratio was lower in the group with higher MDR1 levels regardless of CYP3A5 genotype during postoperative week 1. Tacrolimus 100-110 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 15226679-7 2004 An analysis of the combination of intestinal MDR1 level and liver CYP3A5 genotype revealed that the tacrolimus C/D ratio was lower in the group with higher MDR1 levels regardless of CYP3A5 genotype during postoperative week 1. Tacrolimus 100-110 ATP binding cassette subfamily B member 1 Homo sapiens 156-160 15307840-0 2004 CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Tacrolimus 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 11-25 15307840-1 2004 This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients. Tacrolimus 120-125 ATP binding cassette subfamily B member 1 Homo sapiens 236-250 15307840-1 2004 This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients. Tacrolimus 120-125 ATP binding cassette subfamily B member 1 Homo sapiens 252-255 15307840-5 2004 A significant increase in intestinal CYP3A4 activity and a significant decrease in hepatic and intestinal PGP activity was seen in patients on CsA in comparison with those on FK506 or Rapa (p < 0.01). Tacrolimus 175-180 ATP binding cassette subfamily B member 1 Homo sapiens 106-109 15316356-6 2004 It has been also demonstrated that there is a link between the polymorphisms of the cytochrome P450 3A5, 3A4 and the multidrug resistance-1 (MDR1) genes, and the daily dose necessary to achieve adequate blood tacrolimus levels. Tacrolimus 209-219 ATP binding cassette subfamily B member 1 Homo sapiens 117-139 15316356-6 2004 It has been also demonstrated that there is a link between the polymorphisms of the cytochrome P450 3A5, 3A4 and the multidrug resistance-1 (MDR1) genes, and the daily dose necessary to achieve adequate blood tacrolimus levels. Tacrolimus 209-219 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 15060513-7 2004 The mRNA levels of MDR1, but not CYP3A4, correlated well with the concentration/oral dose ratio and the oral dosage of tacrolimus. Tacrolimus 119-129 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 15060513-8 2004 The good progress after transplantation in both cases suggested that monitoring the change in expression of MDR1 mRNA in the graft intestine might be helpful for understanding the pharmacokinetic profile and determining when to change the route of tacrolimus administration in small-bowel transplant recipients. Tacrolimus 248-258 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 15244495-7 2004 Factors reported to influence the pharmacokinetics of tacrolimus include the patient group studied, hepatic dysfunction, hepatitis C status, time after transplantation, patient age, donor liver characteristics, recipient race, haematocrit and albumin concentrations, diurnal rhythm, food administration, corticosteroid dosage, diarrhoea and cytochrome P450 (CYP) isoenzyme and P-glycoprotein expression. Tacrolimus 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 377-391 15167702-4 2004 The objective of this study was to investigate the effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood concentrations in stable transplant patients. Tacrolimus 119-129 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 14747421-2 2004 A previous study by the authors identified a correlation between the tacrolimus blood level per dose with CYP3A5 and MDR1 gene polymorphisms in pediatric heart transplant patients. Tacrolimus 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 14747421-1 2004 Tacrolimus is a potent immunosuppressive agent used in lung transplantation and is a substrate for both P-glycoprotein (P-gp, encoded by the gene MDR1) and cytochrome (CYP) P4503A. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 14747421-1 2004 Tacrolimus is a potent immunosuppressive agent used in lung transplantation and is a substrate for both P-glycoprotein (P-gp, encoded by the gene MDR1) and cytochrome (CYP) P4503A. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 14747421-1 2004 Tacrolimus is a potent immunosuppressive agent used in lung transplantation and is a substrate for both P-glycoprotein (P-gp, encoded by the gene MDR1) and cytochrome (CYP) P4503A. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 14551375-1 2003 BACKGROUND: Tacrolimus is an immunosuppressive drug that is a substrate of cytochrome P450 3A (CYP3A) enzymes and P-glycoprotein (P-gp). Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 14564197-9 2003 Two polymorphisms (C3435T and G2677[A/T]) of the MDR-1 gene have been shown to influence the bioavailability and toxicity of tacrolimus and cyclosporin. Tacrolimus 125-135 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 14551375-1 2003 BACKGROUND: Tacrolimus is an immunosuppressive drug that is a substrate of cytochrome P450 3A (CYP3A) enzymes and P-glycoprotein (P-gp). Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 12819250-0 2003 Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. Tacrolimus 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 19-41 12818377-5 2003 The Pgp-mediated tacrolimus transport was the highest on day 1 and the lowest on day 11. Tacrolimus 17-27 ATP binding cassette subfamily B member 1 Homo sapiens 4-7 12966368-0 2003 Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Tacrolimus 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 12966368-3 2003 OBJECTIVE: Our objective was to determine the role of genetic polymorphisms in CYP3A4, CYP3A5, and MDR-1 with respect to interindividual variability in cyclosporine and tacrolimus pharmacokinetics. Tacrolimus 169-179 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 12819250-1 2003 The immunosuppressive drug tacrolimus, whose pharmacokinetic characteristics display large interindividual variations, is a substrate for P-glycoprotein (P-gp), the product of the multidrug resistance-1 (MDR1) gene. Tacrolimus 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 138-152 12819250-1 2003 The immunosuppressive drug tacrolimus, whose pharmacokinetic characteristics display large interindividual variations, is a substrate for P-glycoprotein (P-gp), the product of the multidrug resistance-1 (MDR1) gene. Tacrolimus 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 154-158 12819250-1 2003 The immunosuppressive drug tacrolimus, whose pharmacokinetic characteristics display large interindividual variations, is a substrate for P-glycoprotein (P-gp), the product of the multidrug resistance-1 (MDR1) gene. Tacrolimus 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 180-202 12819250-1 2003 The immunosuppressive drug tacrolimus, whose pharmacokinetic characteristics display large interindividual variations, is a substrate for P-glycoprotein (P-gp), the product of the multidrug resistance-1 (MDR1) gene. Tacrolimus 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 204-208 12819250-3 2003 Because P-gp is known to control tacrolimus intestinal absorption, it was postulated that these polymorphisms are associated with tacrolimus pharmacokinetic variations in renal transplant recipients. Tacrolimus 33-43 ATP binding cassette subfamily B member 1 Homo sapiens 8-12 12819250-3 2003 Because P-gp is known to control tacrolimus intestinal absorption, it was postulated that these polymorphisms are associated with tacrolimus pharmacokinetic variations in renal transplant recipients. Tacrolimus 130-140 ATP binding cassette subfamily B member 1 Homo sapiens 8-12 12819250-10 2003 Genotype monitoring of the MDR1 gene reliably predicts the optimal dose of tacrolimus in renal transplant recipients and may predict the initial daily dose needed by individual patients to obtain adequate immunosuppression. Tacrolimus 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 12694072-0 2003 Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 12694072-1 2003 Tacrolimus is a substrate for P-glycoprotein (P-gp) and cytochrome (CYP) P4503A. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 12694072-1 2003 Tacrolimus is a substrate for P-glycoprotein (P-gp) and cytochrome (CYP) P4503A. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 12694072-2 2003 P-gp is encoded by the multiple drug resistance gene MDR1 and CYP3A is the major enzyme responsible for tacrolimus metabolism. Tacrolimus 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 12694072-2 2003 P-gp is encoded by the multiple drug resistance gene MDR1 and CYP3A is the major enzyme responsible for tacrolimus metabolism. Tacrolimus 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 12694072-4 2003 The objective of this study was to evaluate whether the MDR1 exon21 and exon26 polymorphisms and the CYP3A5 polymorphism are associated with tacrolimus disposition in pediatric heart transplant patients. Tacrolimus 141-151 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 12694072-7 2003 We conclude that specific genotypes of MDR1 and CYP3A5 in pediatric heart transplant patients require larger tacrolimus doses to maintain their tacrolimus blood concentration, and that this information could be used prospectively to manage patient"s immunosuppressive therapy. Tacrolimus 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 12694072-7 2003 We conclude that specific genotypes of MDR1 and CYP3A5 in pediatric heart transplant patients require larger tacrolimus doses to maintain their tacrolimus blood concentration, and that this information could be used prospectively to manage patient"s immunosuppressive therapy. Tacrolimus 144-154 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 12490779-4 2002 METHODS: The dose-normalized blood concentrations of tacrolimus at 3 months after renal transplantation were related to CYP3AP1 and multiple drug resistance (MDR)-1 genotypes determined by polymerase chain reaction followed by restriction fragment length polymorphism analysis. Tacrolimus 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 132-164 12352921-0 2002 Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Tacrolimus 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 12451243-0 2002 Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Tacrolimus 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 12451243-10 2002 CONCLUSION: Our results indicate that the decrease in the blood FK506 concentration caused by high-dose steroid therapy is a consequence of the induction of P-glycoprotein and CYP3A in the liver and intestine, and these changes were reversed within 2 weeks after cessation of steroid therapy. Tacrolimus 64-69 ATP binding cassette subfamily B member 1 Homo sapiens 157-171 12352921-0 2002 Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Tacrolimus 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 12352921-1 2002 BACKGROUND: Tacrolimus is a substrate of P-glycoprotein (PGP) encoded by the multidrug resistant (MDR)1 gene (ABCB1). Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 12352921-1 2002 BACKGROUND: Tacrolimus is a substrate of P-glycoprotein (PGP) encoded by the multidrug resistant (MDR)1 gene (ABCB1). Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 57-60 12352921-1 2002 BACKGROUND: Tacrolimus is a substrate of P-glycoprotein (PGP) encoded by the multidrug resistant (MDR)1 gene (ABCB1). Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 12352921-1 2002 BACKGROUND: Tacrolimus is a substrate of P-glycoprotein (PGP) encoded by the multidrug resistant (MDR)1 gene (ABCB1). Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 12352921-2 2002 PGP, a multidrug efflux pump, restricts the distribution of tacrolimus in the brain. Tacrolimus 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 12352921-3 2002 In this study, we investigate the correlation of ABCB1 gene polymorphism with tacrolimus-induced neurotoxicity in patients after liver transplantation. Tacrolimus 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 12352921-7 2002 CONCLUSION: It is indicated that blood concentrations, liver function, graft weight, and polymorphism in the ABCB1 gene are important factors in tacrolimus-induced neurotoxicity. Tacrolimus 145-155 ATP binding cassette subfamily B member 1 Homo sapiens 109-114 12190331-8 2002 Interaction of other drugs with P-glycoprotein may change tacrolimus tissue distribution and modify its toxicity and immunosuppressive activity. Tacrolimus 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 32-46 12172213-2 2002 In the present study, we analyzed whether genetic polymorphism of the MDR1 had some influence on the intestinal expression levels of Pgp and CYP3A4 and the tacrolimus concentration/dose ratio over the first postoperative days in recipients of living-donor liver transplantation (LDLT). Tacrolimus 156-166 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 12190331-2 2002 As a substrate of cytochrome P450 (CYP) 3A enzymes and P-glycoprotein, tacrolimus interacts with several other drugs used in transplantation medicine, which also are known CYP3A and/or P-glycoprotein inhibitors and/or inducers. Tacrolimus 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 11865967-1 2002 Cyclosporine and tacrolimus are substrates and potent inhibitors of the multidrug transporter, P-glycoprotein, in vitro. Tacrolimus 17-27 ATP binding cassette subfamily B member 1 Homo sapiens 95-109 12190331-2 2002 As a substrate of cytochrome P450 (CYP) 3A enzymes and P-glycoprotein, tacrolimus interacts with several other drugs used in transplantation medicine, which also are known CYP3A and/or P-glycoprotein inhibitors and/or inducers. Tacrolimus 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 185-199 11808341-7 2002 In addition, the intestinal P-glycoprotein was suggested to act as an absorptive barrier for tacrolimus in recipients of liver and small bowel transplantation. Tacrolimus 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 28-42 12190331-3 2002 In clinical studies, CYP3A/P-glycoprotein inhibitors and inducers primarily affect oral bioavailability of tacrolimus rather than its clearance, indicating a key role of intestinal P-glycoprotein and CYP3A. Tacrolimus 107-117 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 12190331-3 2002 In clinical studies, CYP3A/P-glycoprotein inhibitors and inducers primarily affect oral bioavailability of tacrolimus rather than its clearance, indicating a key role of intestinal P-glycoprotein and CYP3A. Tacrolimus 107-117 ATP binding cassette subfamily B member 1 Homo sapiens 181-195 12190331-7 2002 P-glycoprotein regulates distribution of tacrolimus through the blood-brain barrier into the brain as well as distribution into lymphocytes. Tacrolimus 41-51 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 12167066-4 2002 Oral bioavailability of tacrolimus can be increased by concomitant administration of inhibitors of either CYP3A or P-glycoprotein. Tacrolimus 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 115-129 11762554-1 2001 Immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids are substrates for the transmembrane multidrug resistance pump P-glycoprotein (P-gp). Tacrolimus 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 11303042-0 2001 Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. Tacrolimus 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 16-30 11762554-1 2001 Immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids are substrates for the transmembrane multidrug resistance pump P-glycoprotein (P-gp). Tacrolimus 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 153-167 11519126-4 2001 We have examined whether the expression levels of the intestinal absorptive barriers, MDR1 gene product P-glycoprotein and cytochrome P450 IIIA4(CYP3A4), correlate with the trough levels of orally administered tacrolimus in a recipient of small bowel transplant for 4 months. Tacrolimus 210-220 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 11519126-4 2001 We have examined whether the expression levels of the intestinal absorptive barriers, MDR1 gene product P-glycoprotein and cytochrome P450 IIIA4(CYP3A4), correlate with the trough levels of orally administered tacrolimus in a recipient of small bowel transplant for 4 months. Tacrolimus 210-220 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 11519126-6 2001 The tacrolimus concentration/dose ratio correlated well with the mRNA expression level of MDR1, but not CYP3A4. Tacrolimus 4-14 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 11519126-7 2001 Intestinal P-glycoprotein rather than CYP3A4 is a good probe to predict the intraindividual variation in the tacrolimus pharmacokinetics. Tacrolimus 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 11-25 11371998-5 2001 RESULTS: The mRNA expression level of MDR1 (r = -0.776), but not CYP3A4 (r = -0.094), was inversely related to the concentration/dose ratio of tacrolimus. Tacrolimus 143-153 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 11371998-8 2001 CONCLUSIONS: Intestinal MDR1 is not only a good probe with which to predict the interindividual variation in tacrolimus pharmacokinetics after LDLT but also a powerful prognostic indicator for the outcome of LDLT. Tacrolimus 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 11303042-9 2001 These results suggested that the enhancing effect of DM-beta-CyD on the oral bioavailability of tacrolimus is due not only to its solubilizing effect but also, at least in part, to its inhibitory effect on the P-gp-mediated efflux of tacrolimus from intestinal epithelial cells. Tacrolimus 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 11303042-9 2001 These results suggested that the enhancing effect of DM-beta-CyD on the oral bioavailability of tacrolimus is due not only to its solubilizing effect but also, at least in part, to its inhibitory effect on the P-gp-mediated efflux of tacrolimus from intestinal epithelial cells. Tacrolimus 234-244 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 10516933-4 1999 The objective of this review is to discuss the effects of P-gp modulation on the pharmacokinetics and the pharmacodynamics of immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids. Tacrolimus 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 11336351-6 2001 The potency of inhibition of P-gp was cyclosporine > tacrolimus > quinidine > verapamil > vinblastine. Tacrolimus 56-66 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 15602799-0 2000 Low levels of lymphocyte MDR1 gene expression during early renal transplantation in patients treated with tacrolimus. Tacrolimus 106-116 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 10731062-3 2000 As CYP3A4 enzymes and P-gp are present at differing concentrations throughout the gastrointestinal tract, the bioavailability of tacrolimus may be influenced by changes in gastrointestinal transit time in addition to changes in hepatic metabolism. Tacrolimus 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 10945321-0 2000 Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Tacrolimus 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 21-35 10945321-1 2000 We have examined whether the expression levels of the intestinal absorptive barriers, MDR1 gene product P-glycoprotein and cytochrome P450 IIIA4 (CYP3A4), correlate with the trough levels of orally administered tacrolimus in a recipient of small bowel transplant for 4 months. Tacrolimus 211-221 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 10945321-1 2000 We have examined whether the expression levels of the intestinal absorptive barriers, MDR1 gene product P-glycoprotein and cytochrome P450 IIIA4 (CYP3A4), correlate with the trough levels of orally administered tacrolimus in a recipient of small bowel transplant for 4 months. Tacrolimus 211-221 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 10945321-5 2000 The tacrolimus concentration/dose ratio correlated well with the mRNA expression level of MDR1, but not CYP3A4. Tacrolimus 4-14 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 10945321-6 2000 These results suggested that intestinal P-glycoprotein rather than CYP3A4 is a good probe to predict the intraindividual variation in the tacrolimus pharmacokinetics during immunosuppressant therapy after small bowel transplantation. Tacrolimus 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 15602799-1 2000 P-glycoprotein (P-gp) is a membrane efflux pump increasing the transport of drugs such as tacrolimus out of the cells. Tacrolimus 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 15602799-1 2000 P-glycoprotein (P-gp) is a membrane efflux pump increasing the transport of drugs such as tacrolimus out of the cells. Tacrolimus 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 15602799-2 2000 The aim of the study was to determine the kinetics of lymphocyte P-gp expression in patients treated with tacrolimus during the first 3 months following renal transplantation. Tacrolimus 106-116 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 10410178-9 1999 DISCUSSION: Tacrolimus is known to be a substrate for P-glycoprotein and metabolized by CYP3A. Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 10837558-4 1997 Cyclosporine and tacrolimus are also substrates for p-glycoprotein, which acts as a counter-transport pump, actively transporting cyclosporine and tacrolimus back into the intestinal lumen. Tacrolimus 17-27 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 9987705-7 1999 Rifampin appears to induce both intestinal and hepatic metabolism of tacrolimus, most likely through induction of CYP3A and P-glycoprotein in the liver and small bowel. Tacrolimus 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 124-138 9567214-11 1998 This way, the detoxicant function of P-gp against products of the ras catabolism could mediate their accumulation when the "vacuum cleaner" function is blocked by CsA or tacrolimus, contributing to the initial development of fibroblastic activation that leads to interstitial fibrosis associated with nephrotoxicity by these immunosuppressor drugs. Tacrolimus 170-180 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 10837558-1 1997 The objective of this section is to evaluate the contributions of hepatic metabolism, intestinal metabolism and intestinal p-glycoprotein to the pharmacokinetics of orally administered cyclosporine and tacrolimus. Tacrolimus 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 123-137 9767529-1 1998 BACKGROUND: The immunosuppressive drugs cyclosporine A (CsA) and tacrolimus (FK506) are extruded from cells by the multidrug resistance P-glycoprotein (P-gp), an efflux pump for drugs and xenobiotics, which may limit their therapeutic effectiveness and/or incidence of toxic side effects. Tacrolimus 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 136-150 9767529-1 1998 BACKGROUND: The immunosuppressive drugs cyclosporine A (CsA) and tacrolimus (FK506) are extruded from cells by the multidrug resistance P-glycoprotein (P-gp), an efflux pump for drugs and xenobiotics, which may limit their therapeutic effectiveness and/or incidence of toxic side effects. Tacrolimus 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 9767529-1 1998 BACKGROUND: The immunosuppressive drugs cyclosporine A (CsA) and tacrolimus (FK506) are extruded from cells by the multidrug resistance P-glycoprotein (P-gp), an efflux pump for drugs and xenobiotics, which may limit their therapeutic effectiveness and/or incidence of toxic side effects. Tacrolimus 77-82 ATP binding cassette subfamily B member 1 Homo sapiens 136-150 9767529-1 1998 BACKGROUND: The immunosuppressive drugs cyclosporine A (CsA) and tacrolimus (FK506) are extruded from cells by the multidrug resistance P-glycoprotein (P-gp), an efflux pump for drugs and xenobiotics, which may limit their therapeutic effectiveness and/or incidence of toxic side effects. Tacrolimus 77-82 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 9767529-2 1998 In the present study, we investigated the effect of therapeutic concentrations of CsA and FK506 on the expression of P-gp in cultured endothelial and proximal tubule cells. Tacrolimus 90-95 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 9767529-8 1998 CONCLUSIONS: The data suggest that the induction of P-gp expression in HAEC and RPTC at concentrations of CsA or FK506 above 0.5 microM is part of the protective answer of cells to toxic concentrations of the drugs and could therefore interfere with the therapeutic effectiveness of CsA in vivo. Tacrolimus 113-118 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 10837558-4 1997 Cyclosporine and tacrolimus are also substrates for p-glycoprotein, which acts as a counter-transport pump, actively transporting cyclosporine and tacrolimus back into the intestinal lumen. Tacrolimus 147-157 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 10837558-14 1997 It seems that compounds that alter (either induce or inhibit) CYP3A4 and/or p-glycoprotein will alter the oral pharmacokinetics of cyclosporine and tacrolimus. Tacrolimus 148-158 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 9246018-1 1997 OBJECTIVE: To quantitate the effect of ketoconazole, an azole antifungal agent and potent inhibitor of CYP3A4 and P-glycoprotein, on the bioavailability of tacrolimus, a substrate of the CYP3A system and of P-glycoprotein. Tacrolimus 156-166 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 9246018-1 1997 OBJECTIVE: To quantitate the effect of ketoconazole, an azole antifungal agent and potent inhibitor of CYP3A4 and P-glycoprotein, on the bioavailability of tacrolimus, a substrate of the CYP3A system and of P-glycoprotein. Tacrolimus 156-166 ATP binding cassette subfamily B member 1 Homo sapiens 207-221 7538609-3 1994 P-glycoprotein also transports MDR modulators such as cyclosporin A, FK506, and calcium channel blockers. Tacrolimus 69-74 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 8702500-8 1996 CsA and FK506 are known to partially overcome Pgp-mediated drug resistance, suggesting the targets of these drugs might regulate Pgp function. Tacrolimus 8-13 ATP binding cassette subfamily B member 1 Homo sapiens 46-49 8702500-8 1996 CsA and FK506 are known to partially overcome Pgp-mediated drug resistance, suggesting the targets of these drugs might regulate Pgp function. Tacrolimus 8-13 ATP binding cassette subfamily B member 1 Homo sapiens 129-132 8702500-12 1996 Our results support the model that immunosuppressants reverse multidrug resistance by competing with other Pgp substrates but reveal that inhibition of FKBP12-dependent Pgp function may also contribute to reversal of multidrug resistance by FK506 and rapamycin. Tacrolimus 241-246 ATP binding cassette subfamily B member 1 Homo sapiens 107-110 8702500-12 1996 Our results support the model that immunosuppressants reverse multidrug resistance by competing with other Pgp substrates but reveal that inhibition of FKBP12-dependent Pgp function may also contribute to reversal of multidrug resistance by FK506 and rapamycin. Tacrolimus 241-246 ATP binding cassette subfamily B member 1 Homo sapiens 169-172 7514263-2 1994 The macrolides FK506 and FK520 stimulate the Pgp-ATPase activity with affinities in the 100 nM range, nearly 10 times higher than that of verapamil, a well known Pgp substrate. Tacrolimus 15-20 ATP binding cassette subfamily B member 1 Homo sapiens 45-48 7514263-2 1994 The macrolides FK506 and FK520 stimulate the Pgp-ATPase activity with affinities in the 100 nM range, nearly 10 times higher than that of verapamil, a well known Pgp substrate. Tacrolimus 15-20 ATP binding cassette subfamily B member 1 Homo sapiens 162-165 19855314-0 2009 Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Tacrolimus 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 1381629-8 1992 This is supported by the ability of FK506 and rapamycin to directly compete the binding of the photoaffinity analogue 125I-iodoaryl azidoprazosin to the P-glycoprotein. Tacrolimus 36-41 ATP binding cassette subfamily B member 1 Homo sapiens 153-167 7681059-0 1993 Human P-glycoprotein transports cyclosporin A and FK506. Tacrolimus 50-55 ATP binding cassette subfamily B member 1 Homo sapiens 6-20 7681059-4 1993 We were interested to determine whether cyclosporin A and FK506 are substrates for P-glycoprotein to transport, and we studied their transcellular transport. Tacrolimus 58-63 ATP binding cassette subfamily B member 1 Homo sapiens 83-97 7681059-10 1993 These results indicate that P-glycoprotein transports the immunosuppressive agents cyclosporin A and FK506. Tacrolimus 101-106 ATP binding cassette subfamily B member 1 Homo sapiens 28-42 34104149-0 2021 Influence of ABCB1 gene polymorphism on concentration to dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients. Tacrolimus 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 34735949-0 2021 Computational validation of ABCB1 gene polymorphism and its effect on tacrolimus dose concentration/levels in renal transplant individuals of South India. Tacrolimus 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 28-33 34269803-8 2021 This synonymous variant in P-glycoprotein may influence the risk of CMV reactivation by altering the efflux of cyclosporine and tacrolimus from donor lymphocytes. Tacrolimus 128-138 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 34483924-5 2021 We present the case of a 16-year-old girl with kidney and liver transplant in whom low concentrations of tacrolimus in the context of low hematocrit led to significant increase in the dosage of tacrolimus and participate, along with a genetic polymorphism of ABCB1, in nephrotoxicity. Tacrolimus 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 259-264 34285488-2 2021 Wuzhi capsule (WZC) could improve tacrolimus blood concentration by inhibiting the metabolism of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp). Tacrolimus 34-44 ATP binding cassette subfamily B member 1 Homo sapiens 128-142 34285488-2 2021 Wuzhi capsule (WZC) could improve tacrolimus blood concentration by inhibiting the metabolism of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp). Tacrolimus 34-44 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 19709321-8 2009 Increased tacrolimus half-life and increased dose interval of sirolimus and tacrolimus were due to CYP3A4/5 and/or P-glycoprotein inhibition by protease inhibitors. Tacrolimus 10-20 ATP binding cassette subfamily B member 1 Homo sapiens 115-129 19709321-8 2009 Increased tacrolimus half-life and increased dose interval of sirolimus and tacrolimus were due to CYP3A4/5 and/or P-glycoprotein inhibition by protease inhibitors. Tacrolimus 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 115-129 34620272-3 2021 Cytochrome-P450 (CYP) isoenzymes CYP3A4 and CYP3A5, as well P-glycoprotein (P-gp) are involved in TAC bioavailability. Tacrolimus 98-101 ATP binding cassette subfamily B member 1 Homo sapiens 60-74 34104149-1 2021 Objective: To evaluate the possible association of ABCB1 single nucleotide polymorphism (SNPs) of the ABCB1 gene with tacrolimus dosages, concentration-to-dose ratios (CDR) and adverse effects in Pakistani liver transplant recipients. Tacrolimus 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 34104149-1 2021 Objective: To evaluate the possible association of ABCB1 single nucleotide polymorphism (SNPs) of the ABCB1 gene with tacrolimus dosages, concentration-to-dose ratios (CDR) and adverse effects in Pakistani liver transplant recipients. Tacrolimus 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 34104149-8 2021 Results: ABCB1 rs1045642 CC genotype showed lower tacrolimus CDR as compared to CT and TT genotype in the first week of the post-transplantation period (p=0.02). Tacrolimus 50-60 ATP binding cassette subfamily B member 1 Homo sapiens 9-14 34104149-10 2021 Conclusion: Identification of ABCB1 rs1045642 polymorphism may shorten the time to achieve optimum levels of tacrolimus during dose titration. Tacrolimus 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 34104149-11 2021 ABCB1 polymorphism rs1045642, rs2032582 and rs1128503 may predict adverse effects in liver transplant recipients receiving tacrolimus. Tacrolimus 123-133 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 35487881-9 2022 After treatment with 5-Aza-2-Dc, the methylation levels of the ABCB1 CpG sites in HepG2 cells significantly decreased, and this was confirmed by pyrosequencing; there was also a significant increase in ABCB1 transcription, which induced a decrease in intracellular tacrolimus concentrations. Tacrolimus 265-275 ATP binding cassette subfamily B member 1 Homo sapiens 63-68 35536394-15 2022 CONCLUSIONS: The CYP3A5 and ABCB1 genotypes impact TAC exposure in PBMCs, which may further alter the effects of TAC. Tacrolimus 51-54 ATP binding cassette subfamily B member 1 Homo sapiens 28-33 35536394-15 2022 CONCLUSIONS: The CYP3A5 and ABCB1 genotypes impact TAC exposure in PBMCs, which may further alter the effects of TAC. Tacrolimus 113-116 ATP binding cassette subfamily B member 1 Homo sapiens 28-33 35487881-1 2022 AIMS: To investigate the effects of ABCB1 DNA methylation in donors on individual differences in tacrolimus blood concentrations following liver transplantation. Tacrolimus 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 35487881-7 2022 RESULTS: Genome-wide methylation sequencing and pyrosequencing analyses showed that the methylation levels of three ABCB1 CpG sites (cg12501229, cg00634941, and cg05496710) were significantly different between groups with different tacrolimus concentration/dose (C0 /D) ratios. Tacrolimus 232-242 ATP binding cassette subfamily B member 1 Homo sapiens 116-121 35487881-8 2022 ABCB1 mRNA expression in donor livers was found to be positively correlated with tacrolimus C0 /D ratio (r = 0.458, P < 0.05). Tacrolimus 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 35487881-9 2022 After treatment with 5-Aza-2-Dc, the methylation levels of the ABCB1 CpG sites in HepG2 cells significantly decreased, and this was confirmed by pyrosequencing; there was also a significant increase in ABCB1 transcription, which induced a decrease in intracellular tacrolimus concentrations. Tacrolimus 265-275 ATP binding cassette subfamily B member 1 Homo sapiens 202-207 35487881-10 2022 CONCLUSIONS: ABCB1 CpG site methylation affects tacrolimus metabolism in humans by regulating ABCB1 expression. Tacrolimus 48-58 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 35487881-10 2022 CONCLUSIONS: ABCB1 CpG site methylation affects tacrolimus metabolism in humans by regulating ABCB1 expression. Tacrolimus 48-58 ATP binding cassette subfamily B member 1 Homo sapiens 94-99 35487881-11 2022 Therefore, ABCB1 DNA methylation in donor livers might be an important epigenetic factor that affects tacrolimus blood concentrations following liver transplantation. Tacrolimus 102-112 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 35132839-15 2022 Single nucleotide variants s in ABCB1 gene might influence the flat pattern peaks of tacrolimus absorption. Tacrolimus 85-95 ATP binding cassette subfamily B member 1 Homo sapiens 32-37 32712713-11 2020 CONCLUSIONS: Flucloxacillin decreases tacrolimus trough levels, possibly through a CYP3A4 and/or P-gp-inducing effect. Tacrolimus 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 34993577-0 2022 Tacrolimus induces remission in refractory and relapsing lupus nephritis by decreasing P-glycoprotein expression and function on peripheral blood lymphocytes. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 34993577-2 2022 Tacrolimus is a P-gp inhibitor and hence, may overcome this resistance. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 34993577-5 2022 Expression and function of P-gp on PBL was measured by flow cytometry (as relative fluorescence index, RFI and Rhodamine dye efflux assay) before and 3 months after tacrolimus therapy. Tacrolimus 165-175 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 34993577-10 2022 Tacrolimus achieves renal response in refractory/relapsing proliferative LN patients which may be partly related to overcoming P-glycoprotein mediated treatment unresponsiveness. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 32803289-7 2021 Subpopulation carrying CYP3A4*1G, CYP3A5*1, ABCB1-3435TT, or SLCO1B3-699AA was presented with enhanced increment in tacrolimus C0/D by 38.8-102.9%. Tacrolimus 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 32803289-8 2021 CONCLUSION: Moderate effect of diltiazem on tacrolimus sparing, which might relate to the polymorphisms of CYP3A4, CYP3A5, ABCB1, and SLCO1B3, was documented. Tacrolimus 44-54 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 33962777-1 2021 Tacrolimus, an immunosuppressant prescribed to reduce the risk of organ rejection, is metabolized by cytochrome P450 and is a substrate for P-glycoprotein. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 140-154 32453653-2 2020 We aimed to establish a population pharmacokinetic (PK) model of tacrolimus and identify clinical covariates, especially the genetic polymorphisms of CYP3A5, ABCB1 and POR*28 that affected the PK to prevent fluctuation in the trough concentration of tacrolimus during the early period after renal transplantation. Tacrolimus 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 158-163 32657689-7 2020 OBJECTIVES: To determine the frequencies and effect of CYP3A5 and adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) polymorphisms on tacrolimus C0/dose ratios in different ethnic groups attending a tertiary renal transplant clinic in SA, and other factors that may explain inter- and IPV in tacrolimus C0. Tacrolimus 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 128-133 31756280-6 2020 Gene screening for CYP3A5 6986 A>G and ABCB1 3435 C>T in organ transplant recipients may help in preventing DDI and facilitating tacrolimus dose adjustment. Tacrolimus 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 32013193-2 2020 Germline mutations in cytochrome P450 isoforms 4 and 5 genes (CYP3A4/5) and the ATP-binding cassette B1 gene (ABCB1) may contribute to interindividual tacrolimus PK variability, which may impact clinical outcomes among allogeneic hematopoietic stem cell transplantation (HSCT) patients. Tacrolimus 151-161 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 32013193-4 2020 Significant associations were detected between germline variants in CYP3A4/5 and ABCB1 and PK endpoints (e.g., median steady-state tacrolimus concentrations and time to goal tacrolimus concentration). Tacrolimus 131-141 ATP binding cassette subfamily B member 1 Homo sapiens 81-86 32013193-4 2020 Significant associations were detected between germline variants in CYP3A4/5 and ABCB1 and PK endpoints (e.g., median steady-state tacrolimus concentrations and time to goal tacrolimus concentration). Tacrolimus 174-184 ATP binding cassette subfamily B member 1 Homo sapiens 81-86 32888708-0 2020 Effect of ABCB1 3435C>T Genetic Polymorphism on Pharmacokinetic Variables of Tacrolimus in Adult Renal Transplant Recipients: a Systematic Review and Meta-analysis. Tacrolimus 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 32888708-1 2020 PURPOSE: Tacrolimus is the substrate of multidrug-resistance 1 (ABCB1). Tacrolimus 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 40-62 32888708-1 2020 PURPOSE: Tacrolimus is the substrate of multidrug-resistance 1 (ABCB1). Tacrolimus 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 64-69 32888708-2 2020 However, the effect of ABCB1 C3435T polymorphism on pharmacokinetic variables of tacrolimus is controversial in different studies. Tacrolimus 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 23-28 32888708-3 2020 This meta-analysis was conducted to explore the relationship between ABCB1 3435C>T genetic polymorphism and pharmacokinetic variables of tacrolimus. Tacrolimus 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 32888708-6 2020 The study explored the relationship between ABCB1 3435C>T genetic polymorphism and pharmacokinetic variables of tacrolimus stratified according to time of posttransplantation, ethnicity, methods of concentration measurement, and the initial doses of tacrolimus. Tacrolimus 112-122 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 32888708-9 2020 The subgroup analysis then revealed that the tacrolimus concentration/weight-adjusted daily dose ratio of ABCB1 3435T carriers was significantly higher than that of the ABCB1 3435CC group at 1 and 6 months. Tacrolimus 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 32888708-10 2020 Meanwhile, ABCB1 3435CT and TT both had a higher tacrolimus concentration/weight-adjusted daily dose ratio compared with ABCB1 3435CC. Tacrolimus 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 32888708-11 2020 IMPLICATIONS: Our meta-analysis identified that the ABCB1 3435C>T genetic polymorphism affected the pharmacokinetic variables of tacrolimus in adult renal transplant recipients. Tacrolimus 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 52-57 32849848-0 2020 Beyond Single Nucleotide Polymorphisms: CYP3A5*3*6*7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients. Tacrolimus 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 67-72 32849848-1 2020 Interpatient variability in tacrolimus pharmacokinetics is attributed to metabolism by cytochrome P-450 3A5 (CYP3A5) isoenzymes and membrane transport by P-glycoprotein. Tacrolimus 28-38 ATP binding cassette subfamily B member 1 Homo sapiens 154-168 32849848-3 2020 Tacrolimus pharmacokinetics was investigated in 65 stable Black and Caucasian post-renal transplant patients by assessing the effects of multiple alleles in both CYP3A5 and ABCB1. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 173-178 32849848-6 2020 Finally, a combined analysis using both CYP3A5 and ABCB1 polymorphisms was developed to assess their inter-related influence on tacrolimus pharmacokinetics. Tacrolimus 128-138 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 32849848-13 2020 The ABCB1 haplotype analysis detected significant associations of the wildtype 1236T-2677T-3435T haplotype to tacrolimus dose (P = 0.03), CL (P = 0.023), CL/LBW (P = 0.022), and AUC* (P = 0.078). Tacrolimus 110-120 ATP binding cassette subfamily B member 1 Homo sapiens 4-9 32849848-14 2020 Finally, analysis combining CYP3A5 and ABCB1 genotypes indicated that the presence of the ABCB1 3435 T allele significantly reduced tacrolimus clearance for all three CPY3A5 metabolic composite groups. Tacrolimus 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 32849848-14 2020 Finally, analysis combining CYP3A5 and ABCB1 genotypes indicated that the presence of the ABCB1 3435 T allele significantly reduced tacrolimus clearance for all three CPY3A5 metabolic composite groups. Tacrolimus 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 90-95 32849848-15 2020 Genotypic associations of tacrolimus pharmacokinetics can be improved by using the novel composite CYP3A5*3*4*5 and ABCB1 haplotypes. Tacrolimus 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 116-121 32849848-16 2020 Consideration of multiple alleles using CYP3A5 metabolic composites and drug transporter ABCB1 haplotypes provides a more comprehensive appraisal of genetic factors contributing to interpatient variability in tacrolimus pharmacokinetics among Whites and Blacks. Tacrolimus 209-219 ATP binding cassette subfamily B member 1 Homo sapiens 89-94 31441337-6 2020 Data Synthesis: Studies demonstrate pharmacokinetic differences between cyclosporine and tacrolimus, particularly with regard to inhibition of 2 hepatic transporters: P-glycoprotein and organic anion transporting polypeptide (OATP). Tacrolimus 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 167-181 31588879-0 2019 Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome. Tacrolimus 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 23-28 31710427-0 2019 Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients. Tacrolimus 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 31710427-3 2019 CYP3A5 and MDR1 single-nucleotide polymorphisms (SNPs) are the most effective polymorphisms that play an significant role in the pharmacokinetics of Tac. Tacrolimus 149-152 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 31454358-0 2019 Retraction: Association of MDR1 Gene SNPs and Haplotypes with the Tacrolimus Dose Requirements in Han Chinese Liver Transplant Recipients. Tacrolimus 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 31922058-0 2020 Melding Pharmacogenomic Effect of MDR1 and CYP3A5 Gene Polymorphism on Tacrolimus Dosing in Renal Transplant Recipients in Northern India. Tacrolimus 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 31922058-10 2020 Of the MDR1 gene SNPs, only the G2677T/A homozygous mutant was significantly associated with TAC level, and it was strongly correlated with P-gp expression.The daily TAC dose requirement was highest with a combination of CYP3A5*1*1 and homozygous mutant TT+AA genotype of G2677T/A, and was lowest with CYP3A5*3*3 and wild-type GG of the G2677T/A genotype. Tacrolimus 166-169 ATP binding cassette subfamily B member 1 Homo sapiens 7-11 31922058-11 2020 Conclusion: Both CYP gene and MDR1 gene polymorphism affect TAC dose requirements, and there is a need to look for both in an individual to achieve the target trough concentration. Tacrolimus 60-63 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 30471066-3 2019 Although cytochrome P450 (CYP) 3A5 and multi-drug resistance 1 (MDR1) polymorphisms influence tacrolimus concentrations, it is unknown if these impact on conversion. Tacrolimus 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 39-62 30471066-3 2019 Although cytochrome P450 (CYP) 3A5 and multi-drug resistance 1 (MDR1) polymorphisms influence tacrolimus concentrations, it is unknown if these impact on conversion. Tacrolimus 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 30597277-0 2019 Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients. Tacrolimus 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 31423060-0 2019 Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients. Tacrolimus 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 24-29 31423060-1 2019 Introduction: Tacrolimus blood levels are influenced by polymorphisms involving Cytochrome 3A subfamily (CYP3A5) and P-Glycoprotein (ABCB-1) genes. Tacrolimus 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 31423060-1 2019 Introduction: Tacrolimus blood levels are influenced by polymorphisms involving Cytochrome 3A subfamily (CYP3A5) and P-Glycoprotein (ABCB-1) genes. Tacrolimus 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 133-139 31423060-4 2019 Methods: An analysis of CYP3A5, ABCB1 genotype done in 101 renal transplant recipients by polymerase chain reaction was correlated with blood tacrolimus trough levels (CLIA method), weight, concentration/dose (L/D) ratio, incidence of biopsy proven early acute rejections, and tacrolimus toxicity. Tacrolimus 142-152 ATP binding cassette subfamily B member 1 Homo sapiens 32-37 31423060-4 2019 Methods: An analysis of CYP3A5, ABCB1 genotype done in 101 renal transplant recipients by polymerase chain reaction was correlated with blood tacrolimus trough levels (CLIA method), weight, concentration/dose (L/D) ratio, incidence of biopsy proven early acute rejections, and tacrolimus toxicity. Tacrolimus 277-287 ATP binding cassette subfamily B member 1 Homo sapiens 32-37 31003147-0 2019 Recipient ABCB1, donor and recipient CYP3A5 genotypes influence tacrolimus pharmacokinetics in liver transplant cases. Tacrolimus 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 31003147-2 2019 METHODS: Meta-analysis was carried out to evaluate how donor/recipient CYP3A5 (n = 678) and recipient ABCB1 (n = 318) genotypes influence tacrolimus pharmacokinetics till one-month of transplantation. Tacrolimus 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 31003147-7 2019 CONCLUSIONS: The donor and recipient CYP3A5*3 polymorphism influences tacrolimus pharmacokinetics in the first month post-transplantation, whereas the association with recipient ABCB1 3435 C > T is inconclusive. Tacrolimus 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 178-183 30597277-10 2019 ABCB1 C2677T was significantly associated with concentrations >15ng/mL (odds ratio, 6.2; 95% confidence interval, 1.8 to 23.6; P = .004) and tacrolimus-related toxicities (odds ratio, 7.5; 95% confidence interval, 1.6 to 55.2; P = .02). Tacrolimus 144-154 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 30597277-12 2019 tacrolimus exposure, whereas ABCB1 C2677T also impacts tacrolimus-related toxicities in stem cell transplants. Tacrolimus 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 30979494-7 2019 CONCLUSION: Wild-type MDR1 gene product P-glycoprotein expressed in the intestine reduces drug absorption from the gastrointestinal tract and may have contributed to low blood levels of tacrolimus in this patient when tacrolimus was orally administered. Tacrolimus 186-196 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 30979494-7 2019 CONCLUSION: Wild-type MDR1 gene product P-glycoprotein expressed in the intestine reduces drug absorption from the gastrointestinal tract and may have contributed to low blood levels of tacrolimus in this patient when tacrolimus was orally administered. Tacrolimus 186-196 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 30979494-7 2019 CONCLUSION: Wild-type MDR1 gene product P-glycoprotein expressed in the intestine reduces drug absorption from the gastrointestinal tract and may have contributed to low blood levels of tacrolimus in this patient when tacrolimus was orally administered. Tacrolimus 218-228 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 30979494-7 2019 CONCLUSION: Wild-type MDR1 gene product P-glycoprotein expressed in the intestine reduces drug absorption from the gastrointestinal tract and may have contributed to low blood levels of tacrolimus in this patient when tacrolimus was orally administered. Tacrolimus 218-228 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 30489455-1 2019 BACKGROUND: CYP3A4/5 and P-glycoprotein (P-gp, ABCB1) affect tacrolimus (TAC) exposure in T cells and kidney cells. Tacrolimus 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 25-39 30713247-8 2019 3) Rheumatoid arthritis patients with a genetic mutation of ATP-binding cassette subfamily B member 1 (ABCB1) had high plasma concentrations of tacrolimus and its 13-O-demethylate. Tacrolimus 144-154 ATP binding cassette subfamily B member 1 Homo sapiens 60-101 30713247-8 2019 3) Rheumatoid arthritis patients with a genetic mutation of ATP-binding cassette subfamily B member 1 (ABCB1) had high plasma concentrations of tacrolimus and its 13-O-demethylate. Tacrolimus 144-154 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 30713247-9 2019 The ABCB1 genetic mutation and associated high plasma concentration of tacrolimus decreased kidney function. Tacrolimus 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 4-9 30489455-1 2019 BACKGROUND: CYP3A4/5 and P-glycoprotein (P-gp, ABCB1) affect tacrolimus (TAC) exposure in T cells and kidney cells. Tacrolimus 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 30489455-1 2019 BACKGROUND: CYP3A4/5 and P-glycoprotein (P-gp, ABCB1) affect tacrolimus (TAC) exposure in T cells and kidney cells. Tacrolimus 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 30489455-1 2019 BACKGROUND: CYP3A4/5 and P-glycoprotein (P-gp, ABCB1) affect tacrolimus (TAC) exposure in T cells and kidney cells. Tacrolimus 73-76 ATP binding cassette subfamily B member 1 Homo sapiens 25-39 30489455-1 2019 BACKGROUND: CYP3A4/5 and P-glycoprotein (P-gp, ABCB1) affect tacrolimus (TAC) exposure in T cells and kidney cells. Tacrolimus 73-76 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 30489455-1 2019 BACKGROUND: CYP3A4/5 and P-glycoprotein (P-gp, ABCB1) affect tacrolimus (TAC) exposure in T cells and kidney cells. Tacrolimus 73-76 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 29689130-5 2018 Genotyping the donor for the ABCB1 c.1199 G>A (exon 11, rs2229109) allele may be of interest before prescribing tacrolimus to the recipient, although this polymorphism is rather rare and its effect may be limited to certain mechanisms of graft loss. Tacrolimus 115-125 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 30166405-4 2018 Additional analyses in 16 healthy volunteers showed that dual pharmacological inhibition of CYP3A4 and P-glycoprotein using itraconazole resulted in increased tacrolimus metabolite/parent ratios (+65%, +112%, and 25% for 13-, 15-, and 31-DMT, respectively; P < 0.01). Tacrolimus 159-169 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 29603629-0 2018 CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. Tacrolimus 79-89 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 29775201-1 2018 Tacrolimus exhibits inter-patient pharmacokinetic variability attributed to CYP3A5 isoenzymes and the efflux transporter, P-glycoprotein. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 122-136 29991328-1 2018 AIM: To investigate the association between donor CYP3A5 and ABCB1 polymorphisms and tacrolimus (Tac)-induced nephrotoxicity and renal function in kidney transplant recipients. Tacrolimus 85-95 ATP binding cassette subfamily B member 1 Homo sapiens 61-66 29920787-2 2018 Single nucleotide polymorphisms (SNPs) in genes important to tacrolimus bioavailability and clearance (ABCB1, CYP3A4, and CYP3A5) are associated with differences in tacrolimus pharmacokinetics. Tacrolimus 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 29920787-2 2018 Single nucleotide polymorphisms (SNPs) in genes important to tacrolimus bioavailability and clearance (ABCB1, CYP3A4, and CYP3A5) are associated with differences in tacrolimus pharmacokinetics. Tacrolimus 165-175 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 29055041-3 2018 It was hypothesized that cytochrome P450 (CYP)3A inhibition of the small intestine by voriconazole and P-glycoprotein (P-gp) inhibition of the small intestine by risperidone exerted a synergistic effect on the bioavailability of tacrolimus. Tacrolimus 229-239 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 29615122-0 2018 Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome. Tacrolimus 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 31-36 29621269-1 2018 The objective of the current study was to explore the role of ABCB1 and CYP3A5 genetic polymorphisms in predicting the bioavailability of tacrolimus and the risk for post-transplant diabetes. Tacrolimus 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 62-67 29621269-5 2018 ABCB1 1236 C>T and 2677G>T/A showed inverse association while CYP3A5*3 showed a positive association with the bioavailability of tacrolimus. Tacrolimus 135-145 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 29055041-0 2018 The possible clinical impact of risperidone on P-glycoprotein-mediated transport of tacrolimus: A case report and in vitro study. Tacrolimus 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 29055041-3 2018 It was hypothesized that cytochrome P450 (CYP)3A inhibition of the small intestine by voriconazole and P-glycoprotein (P-gp) inhibition of the small intestine by risperidone exerted a synergistic effect on the bioavailability of tacrolimus. Tacrolimus 229-239 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 29055041-4 2018 The aim of the present study was to evaluate the effect of risperidone on the P-gp-mediated transport of tacrolimus. Tacrolimus 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 30251601-0 2018 Influence of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics/Pharmacodynamics of Tacrolimus in Pediatric Patients. Tacrolimus 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 23-28 30251601-4 2018 This article focuses on the effects of ABCB1 and CYP3A SNPs on tacrolimus in children who are undergoing organ transplantations. Tacrolimus 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 30251601-9 2018 However, although the amount of literature is limited, it does show a link between ABCB1 SNPs and tacrolimus pharmacodynamics. Tacrolimus 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 28094348-0 2018 Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. Tacrolimus 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 28135009-4 2017 We aimed to investigate the influence of both CYP3A5 and ABCB1 polymorphisms on the efficacy of tacrolimus in ulcerative colitis treatment under the tight dose-adjusting strategy. Tacrolimus 96-106 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 27378609-0 2017 Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype. Tacrolimus 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 28135009-0 2017 ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. Tacrolimus 112-122 ATP binding cassette subfamily B member 1 Homo sapiens 0-41 28655393-0 2017 The role of single nucleotide polymorphisms of CYP3A and ABCB1 on tacrolimus predose concentration in kidney transplant recipients. Tacrolimus 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 28135009-2 2017 Both cytochrome P-450 3A5 (CYP3A5) and ATP-binding cassette subfamily B member 1 (ABCB1) associated with tacrolimus metabolism are known to have several genetic polymorphisms. Tacrolimus 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 39-80 28135009-2 2017 Both cytochrome P-450 3A5 (CYP3A5) and ATP-binding cassette subfamily B member 1 (ABCB1) associated with tacrolimus metabolism are known to have several genetic polymorphisms. Tacrolimus 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 82-87 28214069-4 2017 Immunosuppressive agents, such as calcineurin inhibitors (tacrolimus, cyclosporine) are substrates of cytochromes P450 3A4 and P-gp. Tacrolimus 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 27503662-1 2016 BACKGROUND The aim of the present study was to investigate the pharmacokinetics of the once-daily tacrolimus formulation (QD form) in relation to polymorphisms of the donor cytochrome P450 family 3 sub-family A polypeptide 5 (CYP3A5) gene and recipient adenosine triphosphate-binding cassette sub-family B member 1 (ABCB1) gene. Tacrolimus 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 253-314 29279557-11 2017 It is notable that genotypes in patients where tacrolimus was not detected in the blood were wild types: 2677G/G and 3435C/C in MDR1. Tacrolimus 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 28164520-0 2016 The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients. Tacrolimus 44-54 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 28164520-1 2016 BACKGROUND: The multidrug resistance 1 gene (ABCB1) encodes P-glycoprotein (PGP), mainly expressed in the liver and engaged in metabolism of drugs including the immunosuppressant tacrolimus (TAC). Tacrolimus 179-189 ATP binding cassette subfamily B member 1 Homo sapiens 16-38 28164520-1 2016 BACKGROUND: The multidrug resistance 1 gene (ABCB1) encodes P-glycoprotein (PGP), mainly expressed in the liver and engaged in metabolism of drugs including the immunosuppressant tacrolimus (TAC). Tacrolimus 179-189 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 28164520-1 2016 BACKGROUND: The multidrug resistance 1 gene (ABCB1) encodes P-glycoprotein (PGP), mainly expressed in the liver and engaged in metabolism of drugs including the immunosuppressant tacrolimus (TAC). Tacrolimus 179-189 ATP binding cassette subfamily B member 1 Homo sapiens 60-74 28164520-1 2016 BACKGROUND: The multidrug resistance 1 gene (ABCB1) encodes P-glycoprotein (PGP), mainly expressed in the liver and engaged in metabolism of drugs including the immunosuppressant tacrolimus (TAC). Tacrolimus 179-189 ATP binding cassette subfamily B member 1 Homo sapiens 76-79 28736028-0 2017 Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. Tacrolimus 20-30 ATP binding cassette subfamily B member 1 Homo sapiens 76-106 28736028-1 2017 BACKGROUND: Individual differences in the pharmacokinetics (PK) of tacrolimus (TAC), an immunosuppressive drug, are reportedly associated with single-nucleotide polymorphisms (SNPs) of cytochrome P450 (CYP) 3A5 and multidrug resistance protein 1 (MDR1). Tacrolimus 67-77 ATP binding cassette subfamily B member 1 Homo sapiens 215-245 28736028-1 2017 BACKGROUND: Individual differences in the pharmacokinetics (PK) of tacrolimus (TAC), an immunosuppressive drug, are reportedly associated with single-nucleotide polymorphisms (SNPs) of cytochrome P450 (CYP) 3A5 and multidrug resistance protein 1 (MDR1). Tacrolimus 67-77 ATP binding cassette subfamily B member 1 Homo sapiens 247-251 27503662-1 2016 BACKGROUND The aim of the present study was to investigate the pharmacokinetics of the once-daily tacrolimus formulation (QD form) in relation to polymorphisms of the donor cytochrome P450 family 3 sub-family A polypeptide 5 (CYP3A5) gene and recipient adenosine triphosphate-binding cassette sub-family B member 1 (ABCB1) gene. Tacrolimus 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 316-321 26784512-0 2016 Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. Tacrolimus 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 6-11 26705892-0 2016 The importance of MDR1 gene polymorphisms for tacrolimus dosage. Tacrolimus 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 26705892-1 2016 Polymorphisms of the multi drug resistance (MDR1) gene cause variability in P-glycoprotein mediated metabolism of tacrolimus. Tacrolimus 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 26705892-2 2016 The aim of this study was to examine the relationship between MDR1 gene single nucleotide polymorphisms (SNPs) and their haplotypes with dosage of tacrolimus in kidney transplant recipients who were cytochrome (CYP) 3A5*3 homozygotes. Tacrolimus 147-157 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 26784512-6 2016 CONCLUSIONS: ABCB1 3435 CC genotype in donor influences early renal function and creatinine recovery in tacrolimus-treated kidney transplant recipients. Tacrolimus 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 26184414-0 2015 Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease. Tacrolimus 68-78 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 26543771-0 2015 CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients. Tacrolimus 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 26543771-1 2015 CYP3A5 and ABCB1 polymorphisms have been shown to influence tacrolimus blood concentrations and dose requirements, but the conclusion in the current reports were inconformity. Tacrolimus 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 25781547-0 2015 ABCB1 (MDR-1) pharmacogenetics of tacrolimus in renal transplanted patients: a Next Generation Sequencing approach. Tacrolimus 34-44 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 25781547-0 2015 ABCB1 (MDR-1) pharmacogenetics of tacrolimus in renal transplanted patients: a Next Generation Sequencing approach. Tacrolimus 34-44 ATP binding cassette subfamily B member 1 Homo sapiens 7-12 26856709-0 2016 Impact of CYP3A5 and MDR-1 gene polymorphisms on the dose and level of tacrolimus among living-donor liver transplanted patients: single center experience. Tacrolimus 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 26856709-1 2016 AIM OF WORK: To assess the impact of Cytochrome P450 3A5 (CYP3A5) and multidrug resistance-1 gene (MDR-1) single nucleotide polymorphisms on the dose and blood level of tacrolimus among liver transplanted patients. Tacrolimus 169-179 ATP binding cassette subfamily B member 1 Homo sapiens 70-92 26856709-1 2016 AIM OF WORK: To assess the impact of Cytochrome P450 3A5 (CYP3A5) and multidrug resistance-1 gene (MDR-1) single nucleotide polymorphisms on the dose and blood level of tacrolimus among liver transplanted patients. Tacrolimus 169-179 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 26770526-2 2015 The genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 in 216 RT patients were detected by PCR-RFLP, the genetic and clinical factors and blood concentration/dose x body weight (C/D) values of tacrolimus were performed the single factor correlation analysis, and established the dose prediction algorithm of tacrolimus by stepwise multiple regression analysis. Tacrolimus 191-201 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 26770526-2 2015 The genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 in 216 RT patients were detected by PCR-RFLP, the genetic and clinical factors and blood concentration/dose x body weight (C/D) values of tacrolimus were performed the single factor correlation analysis, and established the dose prediction algorithm of tacrolimus by stepwise multiple regression analysis. Tacrolimus 306-316 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 26450467-0 2015 Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients. Tacrolimus 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 35-40 26450467-3 2015 The objective of this study was to investigate the influence of CYP3A5 and MDR1 allelic variants and their correlation on the pharmacokinetics of tacrolimus and a modified release formulation of tacrolimus in stable patients with liver transplant. Tacrolimus 146-156 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 26450467-3 2015 The objective of this study was to investigate the influence of CYP3A5 and MDR1 allelic variants and their correlation on the pharmacokinetics of tacrolimus and a modified release formulation of tacrolimus in stable patients with liver transplant. Tacrolimus 195-205 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 28356851-1 2015 BACKGROUND: The primary goal of this study was to evaluate the influence of cytochrome P450 (CYP) 3A5 (6986A>G) and ABCB1 (3435C>T) polymorphisms on tacrolimus (TAC) dosage regimen and exposure. Tacrolimus 155-165 ATP binding cassette subfamily B member 1 Homo sapiens 119-124 26622455-0 2015 Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function. Tacrolimus 115-125 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 25916520-5 2015 PATIENTS & METHODS: The correlation between the levels of mRNA specific for key enzymes SXR, CYP3A and ABCB1 involved in the metabolism of tacrolimus was evaluated in PBMCs obtained from a selected population of 29 young kidney transplant recipients. Tacrolimus 143-153 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 26307985-3 2015 We evaluated SNPs in genes that have previously shown correlations in other kinds of solid organ transplantation, namely ABCB1 and CYP3A5 genes with tacrolimus (Tac) and ABCC2, UGT1A9 and SLCO1B1 genes with mycophenolic acid (MPA), during the first six months after lung transplantation (51 patients). Tacrolimus 149-159 ATP binding cassette subfamily B member 1 Homo sapiens 121-126 25817604-0 2015 ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis. Tacrolimus 41-51 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 25817604-1 2015 BACKGROUND: This study aimed to evaluate the blood exposure of and clinical responses to tacrolimus based on genetic variants of CYP3A5 and ABCB1 in patients with rheumatoid arthritis. Tacrolimus 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 140-145 25817604-7 2015 The ABCB1 3435TT group had higher dose-normalized blood concentrations of tacrolimus and 13-O-demethylate. Tacrolimus 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 4-9 25817604-12 2015 ABCB1 C3435T led to a higher blood exposure of tacrolimus and its major metabolite. Tacrolimus 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 25817604-13 2015 The ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affected renal function in rheumatoid arthritis patients. Tacrolimus 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 4-9 25673014-0 2015 The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. Tacrolimus 107-117 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 25673014-0 2015 The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. Tacrolimus 107-117 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 25673014-2 2015 The donor ABCB1 polymorphisms have been related with chronic histological damage and long-term renal function among kidney transplanted patients who received cyclosporine A and tacrolimus (Tac). Tacrolimus 177-187 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 25673014-2 2015 The donor ABCB1 polymorphisms have been related with chronic histological damage and long-term renal function among kidney transplanted patients who received cyclosporine A and tacrolimus (Tac). Tacrolimus 189-192 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 25590378-15 2015 Tacrolimus disappearance was about two-fold higher in cell lines with the combined CYP3A5*1/ABCB1 3435TT genotype versus other genotype combinations. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 92-97 25590378-19 2015 In particular, ciPTC with the combined CYP3A5*1/ABCB1 3435TT genotype demonstrated higher tacrolimus disappearance versus ciPTCs with a different pharmacogenetic profile. Tacrolimus 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 26228923-4 2015 CYP3A4*1G, MDR1 1236-2677-3435 diplotype and NR1I2 -25385C > T explained 21.4% of variability of tacrolimus C0D7/D in CYP3A5 nonexpressers. Tacrolimus 100-110 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 26228923-6 2015 Genotyping of CYP3A4/MDR1/NR1I2 polymorphisms may be helpful for better guiding tacrolimus dosing in CYP3A5 nonexpressers. Tacrolimus 80-90 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 25521359-0 2014 Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients. Tacrolimus 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 6-11 24739669-3 2014 We thus assessed the role of genetic variation in CYP3A4, CYP3A5, POR, NR1I2, and ABCB1 acting jointly in immunosuppressive drug pathways in tacrolimus (TAC) and ciclosporin (CSA) dose requirement in HTx recipients. Tacrolimus 141-151 ATP binding cassette subfamily B member 1 Homo sapiens 82-87 24656020-1 2014 BACKGROUND: The bioavailability of oral tacrolimus is influenced by enterocyte metabolism, which involves CYP3A and P-glycoprotein. Tacrolimus 40-50 ATP binding cassette subfamily B member 1 Homo sapiens 116-130 25242754-1 2014 BACKGROUND: The single-nucleotide polymorphisms (SNPs) of the Multidrug resistance 1 (MDR1) gene have been associated with changes in the pharmacokinetics of cyclosporine (CsA) and tacrolimus (FK506). Tacrolimus 181-191 ATP binding cassette subfamily B member 1 Homo sapiens 62-84 25242754-1 2014 BACKGROUND: The single-nucleotide polymorphisms (SNPs) of the Multidrug resistance 1 (MDR1) gene have been associated with changes in the pharmacokinetics of cyclosporine (CsA) and tacrolimus (FK506). Tacrolimus 181-191 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 25242754-1 2014 BACKGROUND: The single-nucleotide polymorphisms (SNPs) of the Multidrug resistance 1 (MDR1) gene have been associated with changes in the pharmacokinetics of cyclosporine (CsA) and tacrolimus (FK506). Tacrolimus 193-198 ATP binding cassette subfamily B member 1 Homo sapiens 62-84 25242754-1 2014 BACKGROUND: The single-nucleotide polymorphisms (SNPs) of the Multidrug resistance 1 (MDR1) gene have been associated with changes in the pharmacokinetics of cyclosporine (CsA) and tacrolimus (FK506). Tacrolimus 193-198 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 24528196-0 2014 Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Tacrolimus 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 24621983-0 2014 ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. Tacrolimus 95-105 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 24621983-1 2014 OBJECTIVE: ATP-binding cassette, subfamily B, member 1 (ABCB1) transporter, or P-glycoprotein, is an efflux protein implicated in the absorption and the distribution of various compounds, including tacrolimus and cyclosporine A. Tacrolimus 198-208 ATP binding cassette subfamily B member 1 Homo sapiens 11-54 24621983-1 2014 OBJECTIVE: ATP-binding cassette, subfamily B, member 1 (ABCB1) transporter, or P-glycoprotein, is an efflux protein implicated in the absorption and the distribution of various compounds, including tacrolimus and cyclosporine A. Tacrolimus 198-208 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 24621983-1 2014 OBJECTIVE: ATP-binding cassette, subfamily B, member 1 (ABCB1) transporter, or P-glycoprotein, is an efflux protein implicated in the absorption and the distribution of various compounds, including tacrolimus and cyclosporine A. Tacrolimus 198-208 ATP binding cassette subfamily B member 1 Homo sapiens 79-93 24621983-2 2014 In vivo studies suggest an association between the ABCB1 1199G>A single nucleotide polymorphism (SNP) and tacrolimus intracellular accumulation. Tacrolimus 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 24621983-5 2014 The impact of the 1199G>A SNP on ABCB1 activity towards rhodamine (Rh123), doxorubicin, vinblastine, tacrolimus and cyclosporine A was assessed by accumulation, cytotoxicity and/or kinetic experiments. Tacrolimus 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 24621983-6 2014 RESULTS: Tacrolimus accumulation was strongly decreased in cells overexpressing the wild-type protein (1199G) compared to control cells, confirming the ability of ABCB1 to transport tacrolimus. Tacrolimus 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 163-168 24621983-6 2014 RESULTS: Tacrolimus accumulation was strongly decreased in cells overexpressing the wild-type protein (1199G) compared to control cells, confirming the ability of ABCB1 to transport tacrolimus. Tacrolimus 182-192 ATP binding cassette subfamily B member 1 Homo sapiens 163-168 24621983-9 2014 CONCLUSION: ABCB1 encoded by the 1199G wild-type allele transports more efficiently tacrolimus in comparison to the 1199A variant protein. Tacrolimus 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 12-17 24658440-5 2014 Recently, different authors have demonstrated that P-gp inhibitors, such as cyclosporine A (CsA) and its analogue Tacrolimus, are able to reduce P-gp expression and or function in SLE, RA and PsA patients. Tacrolimus 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 24658440-5 2014 Recently, different authors have demonstrated that P-gp inhibitors, such as cyclosporine A (CsA) and its analogue Tacrolimus, are able to reduce P-gp expression and or function in SLE, RA and PsA patients. Tacrolimus 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 24621983-10 2014 This observation indicates that the amino-acid substitution (Ser400Asn) encoded by the 1199A allele drastically decreases the ability of ABCB1 to drive the efflux of tacrolimus in a substrate-specific manner, in agreement with our previously published clinical data. Tacrolimus 166-176 ATP binding cassette subfamily B member 1 Homo sapiens 137-142 24033383-1 2014 BACKGROUND AND AIM: The pharmacokinetics of tacrolimus (Tac) differ among individuals, and genetic polymorphisms of cytochrome P-450 (CYP) 3A4, CYP3A5, and ABCB1 are thought to be involved. Tacrolimus 44-54 ATP binding cassette subfamily B member 1 Homo sapiens 156-161 24120259-4 2013 Recent data have also shown that polymorphism in exon 26 (C3435T) of the multidrug resistance gene (MDR1) was correlated with the expression level and function of P-glycoprotein in the lower duodenum, making the relationship between polymorphism of MDR1 and the effective dose of tacrolimus a source of controversy. Tacrolimus 280-290 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 24042126-0 2013 The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis. Tacrolimus 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 24042126-1 2013 OBJECTIVES: The effect of ABCB1 C3435T SNP on the pharmacokinetics of immunosuppressive drug tacrolimus in different studies was conflicting. Tacrolimus 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 24042126-2 2013 So a meta-analysis was employed to study the correlation of ABCB1 C3435T SNP and the pharmacokinetics of tacrolimus at different post-transplantation times. Tacrolimus 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 24042126-3 2013 METHOD: Several studies about ABCB1 C3435T polymorphism and the pharmacokinetics of tacrolimus were collected through the search on PubMed and the Cochrane Library. Tacrolimus 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 24042126-10 2013 CONCLUSION: Through this meta-analysis for the including studies about the pharmacokinetics of tacrolimus and ABCB1 C3435T SNP, several significant associations were obtained. Tacrolimus 95-105 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 24120259-4 2013 Recent data have also shown that polymorphism in exon 26 (C3435T) of the multidrug resistance gene (MDR1) was correlated with the expression level and function of P-glycoprotein in the lower duodenum, making the relationship between polymorphism of MDR1 and the effective dose of tacrolimus a source of controversy. Tacrolimus 280-290 ATP binding cassette subfamily B member 1 Homo sapiens 163-177 24120259-4 2013 Recent data have also shown that polymorphism in exon 26 (C3435T) of the multidrug resistance gene (MDR1) was correlated with the expression level and function of P-glycoprotein in the lower duodenum, making the relationship between polymorphism of MDR1 and the effective dose of tacrolimus a source of controversy. Tacrolimus 280-290 ATP binding cassette subfamily B member 1 Homo sapiens 249-253 24120259-5 2013 OBJECTIVES: This study investigated the influence of genetic polymorphisms of CYP3A5 and MDR1 on the dose requirements for the induction and maintenance phases of tacrolimus therapy in kidney transplant recipients. Tacrolimus 163-173 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 23990505-9 2013 The differences among ABCB1 genotypes in terms of adverse events and normalized tacrolimus levels were only observed in the first 3 months of therapy. Tacrolimus 80-90 ATP binding cassette subfamily B member 1 Homo sapiens 22-27 23900887-0 2013 Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. Tacrolimus 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 41-46 24231473-0 2013 The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients. Tacrolimus 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 24687344-4 2013 In regard to the clinical implications of MDR1 SNPs, it was found in large meta-analysis that C3435T SNP was associated with a slight increase in the susceptibility to ulcerative colitis and cancer and was related with slight modifications in tacrolimus pharmacokinetics and platinum-based chemotherapy response in lung cancer. Tacrolimus 243-253 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 23633119-3 2013 Tacrolimus is mainly metabolized by cytochrome P450 (CYP) 3A4 and 3A5 and effluxed via ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), encoded by ABCB1 gene. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 135-149 23633119-3 2013 Tacrolimus is mainly metabolized by cytochrome P450 (CYP) 3A4 and 3A5 and effluxed via ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), encoded by ABCB1 gene. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 23633119-3 2013 Tacrolimus is mainly metabolized by cytochrome P450 (CYP) 3A4 and 3A5 and effluxed via ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), encoded by ABCB1 gene. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 169-174 23633119-6 2013 In addition, the involvement of other efflux transporters than P-gp in tacrolimus disposition is uncertain. Tacrolimus 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 23574377-1 2013 WHAT IS KNOWN AND OBJECTIVE: Tacrolimus has a narrow therapeutic index and shows large interindividual variations in pharmacokinetics, which may be partly explained by genetic variability in metabolic enzymes of the cytochrome P450 (mainly CYP3A4 and CYP3A5) and transport P-glycoprotein (encoded by the ABCB1 gene). Tacrolimus 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 273-287 23574377-1 2013 WHAT IS KNOWN AND OBJECTIVE: Tacrolimus has a narrow therapeutic index and shows large interindividual variations in pharmacokinetics, which may be partly explained by genetic variability in metabolic enzymes of the cytochrome P450 (mainly CYP3A4 and CYP3A5) and transport P-glycoprotein (encoded by the ABCB1 gene). Tacrolimus 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 304-309 23743668-0 2013 Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Tacrolimus 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 23743668-7 2013 In addition, the ABCB1 genotype of 36 tacrolimus-treated renal transplant patients was related to ABCB1 activity and tacrolimus efficacy. Tacrolimus 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 23743668-7 2013 In addition, the ABCB1 genotype of 36 tacrolimus-treated renal transplant patients was related to ABCB1 activity and tacrolimus efficacy. Tacrolimus 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 23743668-7 2013 In addition, the ABCB1 genotype of 36 tacrolimus-treated renal transplant patients was related to ABCB1 activity and tacrolimus efficacy. Tacrolimus 117-127 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 23743668-12 2013 This effect on tacrolimus pharmacodynamics was associated with ABCB1 3435C>T SNP in renal transplant patients: verapamil reduced the percentage of IL-2-producing CD4 and CD8 T cells by 14% and 22% in patients with the CC genotype (P < 0.05) but not in patients with the TT genotype. Tacrolimus 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 63-68 23743668-14 2013 CONCLUSION: The ABCB1 3435C>T SNP influences ABCB1 activity of T cells and the pharmacodynamic effect of tacrolimus in kidney transplant patients. Tacrolimus 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 16-21 23743668-14 2013 CONCLUSION: The ABCB1 3435C>T SNP influences ABCB1 activity of T cells and the pharmacodynamic effect of tacrolimus in kidney transplant patients. Tacrolimus 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 24059111-0 2013 [Association of CYP3A5 and MDR1 genetic polymorphisms with the blood concentration of tacrolimus in Chinese liver and renal transplant recipients]. Tacrolimus 86-96 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 24059111-1 2013 OBJECTIVE: To investigate the association of CYP3A5 and MDR1 genetic polymorphisms with the concentration/ dose (C/D) ratio of tacrolimus for the feasibility of individualized medication. Tacrolimus 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 23622581-0 2013 Effect of MDR1 polymorphisms on the blood concentrations of tacrolimus in Turkish renal transplant patients. Tacrolimus 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 10-14 23617933-2 2013 The CYP3A4*18, CYP3A5*3, and MDR1-3435 variant alleles are very important, particularly in tacrolimus metabolism in organ transplant rejection. Tacrolimus 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 23274970-7 2013 The lower fetal blood concentrations are likely due to active efflux transport of tacrolimus from the fetus toward the mother by placental P-glycoprotein. Tacrolimus 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 139-153 23622581-4 2013 This study investigated associations of MDR1 gene C3435T polymorphism with tacrolimus blood concentrations and dose requirements as well as acute rejection episodes among Turkish renal transplant patients. Tacrolimus 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 23622581-13 2013 CONCLUSIONS: Determination of MDR1 polymorphism may help to achieve target of tacrolimus blood concentrations. Tacrolimus 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 22183771-5 2012 The influence of ABCB1 polymorphisms on the pharmacokinetics or complications of tacrolimus was less certain in our study. Tacrolimus 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 22504573-0 2012 Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Tacrolimus 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 22504573-1 2012 BACKGROUND: The published data revealed conflicting results of the polymorphism of MDR1 exon 26 SNP C3435T on the pharmacokinetics of tacrolimus in different post transplant times; thus, the aim was to perform a meta-analysis of different post transplant times to investigate the influence of SNP C3435T on the tacrolimus pharmacokinetics. Tacrolimus 134-144 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 22504573-6 2012 CONCLUSIONS: Our meta-analysis of available studies has demonstrated a definite correlation between the SNP C3435T in MDR1 gene and pharmacokinetics of tacrolimus. Tacrolimus 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 23364483-0 2013 CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). Tacrolimus 86-96 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 23107770-0 2013 Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Tacrolimus 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 32-37 23107770-2 2013 The oral bioavailability of tacrolimus varies greatly between individuals and depends largely on the activity of both the cytochrome P450 3A (CYP3A) subfamily and P-glycoprotein (P-gp). Tacrolimus 28-38 ATP binding cassette subfamily B member 1 Homo sapiens 163-177 23107770-2 2013 The oral bioavailability of tacrolimus varies greatly between individuals and depends largely on the activity of both the cytochrome P450 3A (CYP3A) subfamily and P-glycoprotein (P-gp). Tacrolimus 28-38 ATP binding cassette subfamily B member 1 Homo sapiens 179-183 23107770-3 2013 The possible influence of single nucleotide polymorphisms (SNPs) of CYP3A subfamily and P-gp (MDR-1) in liver transplant recipients has recently been indicated as one of the most important variables affecting the pharmacokinetics of tacrolimus and the renal injury induced by tacrolimus. Tacrolimus 233-243 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 23107770-3 2013 The possible influence of single nucleotide polymorphisms (SNPs) of CYP3A subfamily and P-gp (MDR-1) in liver transplant recipients has recently been indicated as one of the most important variables affecting the pharmacokinetics of tacrolimus and the renal injury induced by tacrolimus. Tacrolimus 233-243 ATP binding cassette subfamily B member 1 Homo sapiens 94-99 23107770-3 2013 The possible influence of single nucleotide polymorphisms (SNPs) of CYP3A subfamily and P-gp (MDR-1) in liver transplant recipients has recently been indicated as one of the most important variables affecting the pharmacokinetics of tacrolimus and the renal injury induced by tacrolimus. Tacrolimus 276-286 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 23107770-3 2013 The possible influence of single nucleotide polymorphisms (SNPs) of CYP3A subfamily and P-gp (MDR-1) in liver transplant recipients has recently been indicated as one of the most important variables affecting the pharmacokinetics of tacrolimus and the renal injury induced by tacrolimus. Tacrolimus 276-286 ATP binding cassette subfamily B member 1 Homo sapiens 94-99 27121561-0 2013 Influence of CYP3A5 6986A > G and ABCB1 3435C > T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. Tacrolimus 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 37-42 27121561-1 2013 The aim of the study is to investigate the influence of ABCB1(3435) and CYP3A5(6986) polymorphisms, tacrolimus troughs and clinical factors on the time of adverse events associated with tacrolimus in pediatric kidney transplant patients. Tacrolimus 186-196 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 23146479-0 2012 Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. Tacrolimus 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 22309416-0 2012 Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population. Tacrolimus 20-30 ATP binding cassette subfamily B member 1 Homo sapiens 85-90 22743729-9 2012 In kidney recipients, associations between donor ABCB1, recipient CCR5 genotype and tacrolimus-induced nephrotoxicity were found. Tacrolimus 84-94 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 22743729-11 2012 In liver recipients, a possible association between recipient ACE, CYP3A5, ABCB1 and CYP2C8 genetic polymorphisms and tacrolimus-induced nephrotoxicity was suggested. Tacrolimus 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 75-80 22743729-14 2012 CONCLUSIONS: Limited evidence suggests that variation in genes involved in pharmacokinetics (ABCB1 and CYP3A5) and pharmacodynamics (TGF-beta, CYP2C8, ACE, CCR5) of tacrolimus may impact a transplant recipients" risk to develop tacrolimus-induced nephrotoxicity across different transplant organ groups. Tacrolimus 165-175 ATP binding cassette subfamily B member 1 Homo sapiens 93-98 22743729-14 2012 CONCLUSIONS: Limited evidence suggests that variation in genes involved in pharmacokinetics (ABCB1 and CYP3A5) and pharmacodynamics (TGF-beta, CYP2C8, ACE, CCR5) of tacrolimus may impact a transplant recipients" risk to develop tacrolimus-induced nephrotoxicity across different transplant organ groups. Tacrolimus 228-238 ATP binding cassette subfamily B member 1 Homo sapiens 93-98 22101623-4 2012 Patients with a small tacrolimus requirement were at increased risk for multiple infections (OR 1.533, p = 0.0008) and higher systolic blood pressure (OR 1.385, p = 0.022) and showed a significant association with the CYP3A5*3/*3 genotype adjusted by MDR1 polymorphisms C3435T and C1236T (OR 8.104, p = 0.0001). Tacrolimus 22-32 ATP binding cassette subfamily B member 1 Homo sapiens 251-255 22309416-2 2012 Tacrolimus is a substrate of cytochrome P-450 3A enzyme and the drug transporter, P-glycoprotein. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 21806386-1 2011 AIM: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus (TAC) in European, North American and Asian populations, with controversial results. Tacrolimus 169-172 ATP binding cassette subfamily B member 1 Homo sapiens 37-42 21677300-0 2011 CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Tacrolimus 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 21677300-1 2011 BACKGROUND: The effect of potentially relevant genetic polymorphisms, CYP3A5 6986A>G and ABCB1 3435C>T, on Tacrolimus pharmacokinetics and graft clinical outcome was investigated in donor and recipient DNA samples from 209 kidney transplant patients. Tacrolimus 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 92-97 21806386-1 2011 AIM: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus (TAC) in European, North American and Asian populations, with controversial results. Tacrolimus 157-167 ATP binding cassette subfamily B member 1 Homo sapiens 37-42 22008665-12 2012 This study identifies IL-18 reduced tacrolimus concentration/dose (C/D) ratio through up regulation of P-glycoprotein (P-gp). Tacrolimus 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 22008665-12 2012 This study identifies IL-18 reduced tacrolimus concentration/dose (C/D) ratio through up regulation of P-glycoprotein (P-gp). Tacrolimus 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 22310591-0 2012 Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Tacrolimus 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 33-74 22310591-1 2012 BACKGROUND: Tacrolimus is a substrate of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), encoded by the CYP3A and ATP-binding cassette subfamily B member 1 (ABCB1) genes, respectively. Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 22310591-1 2012 BACKGROUND: Tacrolimus is a substrate of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), encoded by the CYP3A and ATP-binding cassette subfamily B member 1 (ABCB1) genes, respectively. Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 22310591-1 2012 BACKGROUND: Tacrolimus is a substrate of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), encoded by the CYP3A and ATP-binding cassette subfamily B member 1 (ABCB1) genes, respectively. Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 120-161 22310591-1 2012 BACKGROUND: Tacrolimus is a substrate of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), encoded by the CYP3A and ATP-binding cassette subfamily B member 1 (ABCB1) genes, respectively. Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 163-168 22310591-2 2012 This study was aimed to investigate the impact of CYP3A and ABCB1 polymorphisms on the tacrolimus pharmacokinetics and clinical outcomes in Korean renal transplant recipients. Tacrolimus 87-97 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 21698374-12 2011 In contrast, in pediatric liver recipients, variation in tacrolimus disposition appears related to age and ABCB1 genotype. Tacrolimus 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 21922127-0 2011 Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Tacrolimus 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 24-29 21922127-1 2011 Tacrolimus is a substrate of cytochrome P4503A (CYP3A) enzymes as well as of the drug transporter ABCB1. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 22016125-8 2011 Calcineurin inhibitors (cyclosporine, tacrolimus) and mTOR inhibitors (sirolimus, everolimus) are particularly susceptible to the effects of substances that inhibit or induce cytochrome P450 (CYP) 3A4 and P-glycoprotein. Tacrolimus 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 205-219 21916909-0 2011 Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. Tacrolimus 85-95 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 21916909-1 2011 WHAT IS KNOWN AND OBJECTIVE: Tacrolimus (TAC) is metabolized mainly by the CYP3A subfamily and extruded into the intestine by P-glycoprotein, which is encoded by the ABCB1 gene. Tacrolimus 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 166-171 21359536-2 2011 Impacts of CYP3A5 and ABCB1 gene polymorphisms on the immunosuppressant tacrolimus have been reported in previous studies of liver transplantation. Tacrolimus 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 22-27 20571034-0 2011 Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period? Tacrolimus 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 21368751-3 2011 We have shown in vitro that ezetimibe and tacrolimus may interact in competition for intestinal UGT1A1 and ABCB1 at concentrations reached in gut lumen after oral administration. Tacrolimus 42-52 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 21839244-0 2011 Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. Tacrolimus 112-122 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 21839244-3 2011 We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation. Tacrolimus 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 20571034-1 2011 Polymorphisms in the drug transporter gene (ABCB1) may play a significant role in individualizing cyclosporine (CsA) and tacrolimus (Tac) dosage and subsequently the allograft outcome in renal transplant recipients. Tacrolimus 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 20571034-1 2011 Polymorphisms in the drug transporter gene (ABCB1) may play a significant role in individualizing cyclosporine (CsA) and tacrolimus (Tac) dosage and subsequently the allograft outcome in renal transplant recipients. Tacrolimus 133-136 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 21289623-0 2011 ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Tacrolimus 48-58 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 21436775-0 2011 Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. Tacrolimus 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 21436775-1 2011 BACKGROUND: The purpose of this study was to investigate the effects of polymorphisms in CYP3A5*3, CYP3AP1, and MDR1, and of haplotype, on plasma levels of tacrolimus in Chinese patients after renal transplantation, and to assess the relationship between polymorphisms and the variability of concentration/dose of tacrolimus for optimization and individualization regimens. Tacrolimus 156-166 ATP binding cassette subfamily B member 1 Homo sapiens 112-116 21318106-8 2011 LS 180 cell line study indicated that Zhi Shi increased the efflux activity of P-gp, enabling us to explain the decreased oral bioavailability of tacrolimus caused by Zhi Shi. Tacrolimus 146-156 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 21076384-2 2010 The effects of genetic polymorphisms of cytochrome P450 3A (CYP3A) 5 and Adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) genes on the achievement of target tacrolimus trough levels and clinical outcomes in renal transplants were evaluated. Tacrolimus 177-187 ATP binding cassette subfamily B member 1 Homo sapiens 73-133 22110582-0 2011 Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. Tacrolimus 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 22110582-7 2011 Tacrolimus C/D ratios of liver transplant recipients varied significantly among different haplotype groups of MDR1 gene. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 20629603-0 2011 Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Tacrolimus 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 10-53 20629603-3 2011 Studies examining interindividual differences in the expression of the ABCB1 (ATP-binding cassette, subfamily B, member 1) gene (which encodes the drug transporter, P-gp) and its genetic polymorphisms have attempted to elucidate variations in tacrolimus response and disposition in children. Tacrolimus 243-253 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 20629603-3 2011 Studies examining interindividual differences in the expression of the ABCB1 (ATP-binding cassette, subfamily B, member 1) gene (which encodes the drug transporter, P-gp) and its genetic polymorphisms have attempted to elucidate variations in tacrolimus response and disposition in children. Tacrolimus 243-253 ATP binding cassette subfamily B member 1 Homo sapiens 78-121 20629603-4 2011 AREAS COVERED IN THIS REVIEW: This review explores pharmacogenetic knowledge developed over the last decade regarding the impact of ABCB1 polymorphisms on tacrolimus toxicity and dosage requirements in children. Tacrolimus 155-165 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 20629603-5 2011 WHAT THE READER WILL GAIN: A better understanding of the role of ABCB1 genetic polymorphisms (and corresponding haplotypes) and ABCB1 expression levels in various tissues and organs on tacrolimus outcomes in children with liver transplant. Tacrolimus 185-195 ATP binding cassette subfamily B member 1 Homo sapiens 65-70 20629603-5 2011 WHAT THE READER WILL GAIN: A better understanding of the role of ABCB1 genetic polymorphisms (and corresponding haplotypes) and ABCB1 expression levels in various tissues and organs on tacrolimus outcomes in children with liver transplant. Tacrolimus 185-195 ATP binding cassette subfamily B member 1 Homo sapiens 128-133 22211008-1 2011 Single nucleotide polymorphisms in CYP3A5 (A6986G) and MDR-1 (C3435T) genes have been shown to be associated with the pharmacokinetics of tacrolimus in case of renal transplant recipients. Tacrolimus 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 21076384-2 2010 The effects of genetic polymorphisms of cytochrome P450 3A (CYP3A) 5 and Adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) genes on the achievement of target tacrolimus trough levels and clinical outcomes in renal transplants were evaluated. Tacrolimus 177-187 ATP binding cassette subfamily B member 1 Homo sapiens 135-140 21094796-0 2010 Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Tacrolimus 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 20876828-8 2010 Tacrolimus, an immunosuppressant, is also a substrate of CYP3A and P-GP. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 21094796-0 2010 Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Tacrolimus 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 21094796-1 2010 The aims of this study were to investigate the influence of CYP3A5 and MDR1 genetic polymorphisms on tacrolimus pharmacokinetics in Chinese renal transplant recipients, so as to help rational administration in clinical practice. Tacrolimus 101-111 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 20415563-0 2010 CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Tacrolimus 41-51 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 20970601-11 2010 CONCLUSION: Intestinal absorption and metabolism of tacrolimus was significantly affected by the SNPs in the CYP3A5 and MDR1 genes, which may offer a useful tool to optimize tacrolimus dosing after renal transplantation. Tacrolimus 52-62 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 20970601-11 2010 CONCLUSION: Intestinal absorption and metabolism of tacrolimus was significantly affected by the SNPs in the CYP3A5 and MDR1 genes, which may offer a useful tool to optimize tacrolimus dosing after renal transplantation. Tacrolimus 174-184 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 21072155-11 2010 However, median L/D ratio for tacrolimus was significantly higher in subjects with CYP3A5*3/*3 (n = 24) (P = 0.011) and MDR- 1 3435TT (n = 18) (P = 0.0122). Tacrolimus 30-40 ATP binding cassette subfamily B member 1 Homo sapiens 120-126 21072155-12 2010 The findings from this study show that homozygous mutant patients for CYP3A5 and MDR-1 gene SNPs could be managed with lower tacrolimus dose to avoid nephrotoxicity. Tacrolimus 125-135 ATP binding cassette subfamily B member 1 Homo sapiens 81-86 20091056-2 2010 We report a renal transplant recipient who suffered from severe nephrotoxicity related to a toxic tacrolimus trough concentration in both conditions, diarrhoea and CCB co-administration, and with genotyped CYP3A system and P-glycoprotein (P-gp) polymorphisms. Tacrolimus 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 239-243 20091056-5 2010 It also highlights the key role in tacrolimus pharmacokinetics of the CYP3A system and P-gp polymorphisms, and their influence in high-risk situations when enzyme activity is already affected by enterocyte damage due to diarrhoea and CCB competition. Tacrolimus 35-45 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 20415563-1 2010 AIMS: This prospective study investigated the effect of genetic polymorphisms in a biotransformation enzyme (CYP3A5) and a transporter protein (ABCB1) on tacrolimus (Tac) whole blood concentrations in renal transplantation, and more specifically on peripheral blood mononuclear cell (PBMC) drug concentrations, after renal transplantation. Tacrolimus 154-164 ATP binding cassette subfamily B member 1 Homo sapiens 144-149 19729569-0 2009 Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. Tacrolimus 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 20080907-0 2010 Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 20080907-10 2010 The response to tacrolimus correlated with P-glycoprotein expression and C/M ratio. Tacrolimus 16-26 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 20080907-13 2010 CONCLUSION: Early efficacy of tacrolimus treatment depended on its inhibitory effect on the drug exclusion function of P-glycoprotein, leading to restoration of intracellular therapeutic levels of corticosteroids and clinical improvement. Tacrolimus 30-40 ATP binding cassette subfamily B member 1 Homo sapiens 119-133 20305320-1 2010 BACKGROUND: Induction of the hepatic and intestinal cytochrome P450-3A4 system and intestinal P-glycoprotein is an unavoidable consequence of rifampin administration which requires substantial increase in tacrolimus dose when given concurrently. Tacrolimus 205-215 ATP binding cassette subfamily B member 1 Homo sapiens 94-108 20305320-11 2010 CONCLUSIONS: We conclude that chronic diarrhea may cause toxic tacrolimus blood levels even in presence of rifampin, this would be due to its significant cytochrome P450-3A4 and P-glycoprotein enzyme inhibitory effect. Tacrolimus 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 178-192 19729569-2 2009 Tacrolimus is a substrate for P-glycoprotein, the product of the ABCB1 gene. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 19729569-2 2009 Tacrolimus is a substrate for P-glycoprotein, the product of the ABCB1 gene. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 65-70 19729569-3 2009 To determine whether the ABCB1 single-nucleotide polymorphism (SNP) 3435C>T was associated with variation in the tacrolimus concentration:dose ratio (C:D) in 42 liver transplant recipients during three months after transplantation. Tacrolimus 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 19729569-18 2009 CONCLUSION: The ABCB1 3435C>T polymorphism influenced the tacrolimus C:D in the first days after liver transplantation. Tacrolimus 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 16-21 19729569-1 2009 PURPOSE: The effect of ABCB1 3435C>T on tacrolimus concentrations in liver transplant recipients was studied. Tacrolimus 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 23-28 19267185-1 2009 PURPOSE: This study investigated whether haplotypes in the multidrug resistance 1 (MDR1) gene had effects on mRNA expression levels of MDR1 and cytochrome P450 (CYP) 3A4, and on the pharmacokinetics of tacrolimus in living-donor liver transplant (LDLT) patients, considering the gender difference. Tacrolimus 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 59-81 19740399-0 2009 Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Tacrolimus 51-61 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 19740399-1 2009 AIMS: The aim of this study was to investigate the influence of genetic polymorphisms in ABCB1 on the incidence of nephrotoxicity and tacrolimus dosage-requirements in paediatric patients following liver transplantation. Tacrolimus 134-144 ATP binding cassette subfamily B member 1 Homo sapiens 89-94 19740399-8 2009 CONCLUSIONS: These findings suggest that ABCB1 polymorphisms in the native intestine significantly influence tacrolimus dosage-requirement in the stable phase after transplantation. Tacrolimus 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 41-46 19740399-10 2009 Genotyping future transplant recipients for ABCB1 polymorphisms, therefore, could have the potential to individualize better tacrolimus immunosuppressive therapy and enhance drug safety. Tacrolimus 125-135 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 19267185-1 2009 PURPOSE: This study investigated whether haplotypes in the multidrug resistance 1 (MDR1) gene had effects on mRNA expression levels of MDR1 and cytochrome P450 (CYP) 3A4, and on the pharmacokinetics of tacrolimus in living-donor liver transplant (LDLT) patients, considering the gender difference. Tacrolimus 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 19267185-6 2009 CONCLUSION: MDR1 haplotype may have a minor association with the tacrolimus pharmacokinetics after LDLT, but could be a good predictor of the inter-individual variation of intestinal expression of CYP3A4 in women. Tacrolimus 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 19384171-0 2009 Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 19688973-1 2009 AIM: P-glycoprotein, the product of the ATP-binding cassette subfamily B member 1 (ABCB1) gene (or the so-called multidrug resistance 1 gene), is an ATP-driven efflux pump contributing to the pharmacokinetics as well as the pharmacokinetics of drugs that are P-glycoprotein substrates, such as tacrolimus. Tacrolimus 294-304 ATP binding cassette subfamily B member 1 Homo sapiens 5-19 19688973-1 2009 AIM: P-glycoprotein, the product of the ATP-binding cassette subfamily B member 1 (ABCB1) gene (or the so-called multidrug resistance 1 gene), is an ATP-driven efflux pump contributing to the pharmacokinetics as well as the pharmacokinetics of drugs that are P-glycoprotein substrates, such as tacrolimus. Tacrolimus 294-304 ATP binding cassette subfamily B member 1 Homo sapiens 40-81 19688973-1 2009 AIM: P-glycoprotein, the product of the ATP-binding cassette subfamily B member 1 (ABCB1) gene (or the so-called multidrug resistance 1 gene), is an ATP-driven efflux pump contributing to the pharmacokinetics as well as the pharmacokinetics of drugs that are P-glycoprotein substrates, such as tacrolimus. Tacrolimus 294-304 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 19688973-1 2009 AIM: P-glycoprotein, the product of the ATP-binding cassette subfamily B member 1 (ABCB1) gene (or the so-called multidrug resistance 1 gene), is an ATP-driven efflux pump contributing to the pharmacokinetics as well as the pharmacokinetics of drugs that are P-glycoprotein substrates, such as tacrolimus. Tacrolimus 294-304 ATP binding cassette subfamily B member 1 Homo sapiens 113-135 19688973-1 2009 AIM: P-glycoprotein, the product of the ATP-binding cassette subfamily B member 1 (ABCB1) gene (or the so-called multidrug resistance 1 gene), is an ATP-driven efflux pump contributing to the pharmacokinetics as well as the pharmacokinetics of drugs that are P-glycoprotein substrates, such as tacrolimus. Tacrolimus 294-304 ATP binding cassette subfamily B member 1 Homo sapiens 259-273 19384171-2 2009 We have determined the genotypic frequencies of the CYP3A and ATP-binding cassette sub-family B member 1 (ABCB1) genes, which encode the CYP3A and P-gp proteins, respectively, in Korean organ transplant recipients and donors, and have assessed the influence of CYP3A and ABCB1 polymorphisms on tacrolimus concentrations. Tacrolimus 294-304 ATP binding cassette subfamily B member 1 Homo sapiens 62-104 19384171-2 2009 We have determined the genotypic frequencies of the CYP3A and ATP-binding cassette sub-family B member 1 (ABCB1) genes, which encode the CYP3A and P-gp proteins, respectively, in Korean organ transplant recipients and donors, and have assessed the influence of CYP3A and ABCB1 polymorphisms on tacrolimus concentrations. Tacrolimus 294-304 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 19384171-2 2009 We have determined the genotypic frequencies of the CYP3A and ATP-binding cassette sub-family B member 1 (ABCB1) genes, which encode the CYP3A and P-gp proteins, respectively, in Korean organ transplant recipients and donors, and have assessed the influence of CYP3A and ABCB1 polymorphisms on tacrolimus concentrations. Tacrolimus 294-304 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 19384171-1 2009 BACKGROUND: Cytochrome P450 3A (CYP3A) and the drug transporter P-glycoprotein (P-gp) affect the bioavailability of tacrolimus, the most commonly used immunosuppressive agent in organ transplant recipients. Tacrolimus 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 64-78 19384171-1 2009 BACKGROUND: Cytochrome P450 3A (CYP3A) and the drug transporter P-glycoprotein (P-gp) affect the bioavailability of tacrolimus, the most commonly used immunosuppressive agent in organ transplant recipients. Tacrolimus 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 19289993-0 2009 The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Tacrolimus 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 19376366-0 2009 Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. Tacrolimus 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 19376366-7 2009 This study showed that subjects in the FK506 group who had encoded the 1236C>T substitution in the MDR1 gene displayed 44.4% higher drug concentrations compared with ("wild-type") individuals. Tacrolimus 39-44 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 19289993-1 2009 BACKGROUND: Tacrolimus is a substrate of cytochrome P-450 (CYP) 3A enzyme and of the drug transporter ABCB1. Tacrolimus 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 19067682-3 2008 Our objective was to determine the influence of CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus daily requirements and on transplantation outcome. Tacrolimus 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 19728747-9 2009 Ciclosporin and tacrolimus have distinct pharmacokinetics, but both are metabolized by intestinal and hepatic CYP3A4/3A5 and transported across the cell membrane by P-glycoprotein. Tacrolimus 16-26 ATP binding cassette subfamily B member 1 Homo sapiens 165-179 19005401-1 2008 BACKGROUND: Bioavailability of tacrolimus (Tac) and cyclosporine is determined by cytochrome P450IIIA and by P-glycoprotein encoded by the CYP3A4/CYP3A5 and ABCB1 genes. Tacrolimus 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 157-162 19114346-8 2008 In terms of pharmacogenomics, the major factors affecting tacrolimus concentration/dosage included MDR1 3435, MDR1 2677 and MDR1 1236 polymorphisms, which vastly varied between the patients early after the operation. Tacrolimus 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 19114346-8 2008 In terms of pharmacogenomics, the major factors affecting tacrolimus concentration/dosage included MDR1 3435, MDR1 2677 and MDR1 1236 polymorphisms, which vastly varied between the patients early after the operation. Tacrolimus 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 19114346-8 2008 In terms of pharmacogenomics, the major factors affecting tacrolimus concentration/dosage included MDR1 3435, MDR1 2677 and MDR1 1236 polymorphisms, which vastly varied between the patients early after the operation. Tacrolimus 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 19100412-0 2008 Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation. Tacrolimus 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 19100412-1 2008 OBJECTIVE: To investigate the differential effects of cyclosporine (CsA) and tacrolimus (TAC) on renal expression of P-glycoprotein (P-gp) in a cohort of kidney transplant recipients. Tacrolimus 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 19100412-1 2008 OBJECTIVE: To investigate the differential effects of cyclosporine (CsA) and tacrolimus (TAC) on renal expression of P-glycoprotein (P-gp) in a cohort of kidney transplant recipients. Tacrolimus 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 19100412-1 2008 OBJECTIVE: To investigate the differential effects of cyclosporine (CsA) and tacrolimus (TAC) on renal expression of P-glycoprotein (P-gp) in a cohort of kidney transplant recipients. Tacrolimus 89-92 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 19100412-1 2008 OBJECTIVE: To investigate the differential effects of cyclosporine (CsA) and tacrolimus (TAC) on renal expression of P-glycoprotein (P-gp) in a cohort of kidney transplant recipients. Tacrolimus 89-92 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 18704002-0 2008 Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Tacrolimus 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 19010156-0 2008 Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Tacrolimus 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 18827354-0 2008 Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells. Tacrolimus 10-20 ATP binding cassette subfamily B member 1 Homo sapiens 51-65 18827354-4 2008 We investigated the effect of this therapeutic dose of tacrolimus on the expression and activity of the multidrug resistance protein 1 (MDR1 or Pgp, P-glycoprotein) and ATP-binding cassette transporters A5 (ABCA5) in human brain microvascular endothelial cells (HBMEC), derived from Blood-Brain Barrier (BBB) endothelium, these being the most predominantly expressed transcripts in these cells. Tacrolimus 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 104-134 18827354-4 2008 We investigated the effect of this therapeutic dose of tacrolimus on the expression and activity of the multidrug resistance protein 1 (MDR1 or Pgp, P-glycoprotein) and ATP-binding cassette transporters A5 (ABCA5) in human brain microvascular endothelial cells (HBMEC), derived from Blood-Brain Barrier (BBB) endothelium, these being the most predominantly expressed transcripts in these cells. Tacrolimus 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 18827354-4 2008 We investigated the effect of this therapeutic dose of tacrolimus on the expression and activity of the multidrug resistance protein 1 (MDR1 or Pgp, P-glycoprotein) and ATP-binding cassette transporters A5 (ABCA5) in human brain microvascular endothelial cells (HBMEC), derived from Blood-Brain Barrier (BBB) endothelium, these being the most predominantly expressed transcripts in these cells. Tacrolimus 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 149-163 18827354-5 2008 The expression and activity of MDR1 transporter decreased with 30 ng/ml tacrolimus. Tacrolimus 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 18704002-2 2008 The aim of this study was to examine the influence of the CYP3A4, CYP3A5, and MDR1 single nucleotide polymorphisms on changes in tacrolimus exposure and dosing in renal allograft recipients treated with fluconazole. Tacrolimus 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 18589174-3 2008 Frequencies of CYP3A5*1 versus *3 and MDR1-C3435T were correlated with tacrolimus (TAC) and cyclosporine (CSA) concentration-to-dose (C/D) ratios. Tacrolimus 71-81 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 18594053-5 2008 DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus. Tacrolimus 175-185 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 18594053-5 2008 DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus. Tacrolimus 175-185 ATP binding cassette subfamily B member 1 Homo sapiens 126-131 18408564-0 2008 Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Tacrolimus 51-61 ATP binding cassette subfamily B member 1 Homo sapiens 10-14 18252812-0 2008 Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation. Tacrolimus 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 42-64 18252812-0 2008 Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation. Tacrolimus 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 65-70 18252812-2 2008 In this study, we examined the significance of multidrug resistance 1 (MDR1) in the peripheral blood cells by comparing the trough concentration of tacrolimus with the occurrence of acute cellular rejection (ACR) in retrospectively collected pediatric living-donor liver transplant patients, who were enrolled after obtaining written informed consent. Tacrolimus 148-158 ATP binding cassette subfamily B member 1 Homo sapiens 47-69 18252812-2 2008 In this study, we examined the significance of multidrug resistance 1 (MDR1) in the peripheral blood cells by comparing the trough concentration of tacrolimus with the occurrence of acute cellular rejection (ACR) in retrospectively collected pediatric living-donor liver transplant patients, who were enrolled after obtaining written informed consent. Tacrolimus 148-158 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 18252812-4 2008 The average trough concentration of tacrolimus during the 15-day postoperative period was significantly higher in the event-free patients than in those who experienced ACR (21 of 44 cases), and they had higher levels of blood MDR1 mRNA. Tacrolimus 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 226-230 18252812-5 2008 In addition, the average trough concentration of tacrolimus significantly correlated with the logarithmically transformed MDR1 mRNA data from the blood cells in patients of both the event-free (r = 0.5406; P = 0.0077) and ACR (r = 0.4772; P = 0.0284). Tacrolimus 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 18252812-7 2008 These results suggest that MDR1 in blood cells decreases the leukocytic concentration of tacrolimus, and it could be a useful marker to establish an individualized target concentration of tacrolimus to prevent ACR in pediatric patients after liver transplantation. Tacrolimus 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 18252812-7 2008 These results suggest that MDR1 in blood cells decreases the leukocytic concentration of tacrolimus, and it could be a useful marker to establish an individualized target concentration of tacrolimus to prevent ACR in pediatric patients after liver transplantation. Tacrolimus 188-198 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 18408564-9 2008 CONCLUSION: These findings suggest that the CYP3A5*1 genotype as well as the MDR1 mRNA level in enterocytes contributes to interindividual variation in the CL/F of tacrolimus in adult recipients early after living-donor liver transplantation. Tacrolimus 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 18408564-0 2008 Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Tacrolimus 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 10-14 17495880-1 2007 The impact of CYP3A and MDR1 gene single-nucleotide polymorphisms on long-term tacrolimus disposition and drug-related toxicity has not been assessed. Tacrolimus 79-89 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 17660216-9 2008 Tacrolimus, a P-gp inhibitor, restored IDLs in RA lymphocytes. Tacrolimus 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 17660216-14 2008 Measurement of P-gp expression on lymphocytes could be a potentially useful marker for assessing drug resistance in RA, and may be suitable for selecting infliximab or DMARDs including tacrolimus for RA treatment. Tacrolimus 185-195 ATP binding cassette subfamily B member 1 Homo sapiens 15-19